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ABSTRACT 
 
This PhD thesis is a study of cortical electrophysiology in two basal ganglia 
disorders: Parkinson’s disease (PD) and dystonia. Two diseases were chosen 
as being representative of hypokinetic and hyperkinetic movement disorders, 
respectively. In addition, current treatments seem to be imperfect to control 
many aspects of both diseases, hence the interest in exploring potential new 
therapeutic targets. PD and dystonia are basal ganglia diseases, but there is 
growing body of evidence of impaired cortical function and particularly of 
abnormal sensorimotor cortical plasticity in both disorders. We however still lack 
knowledge about functional significance of these cortical changes. Are they 
maladaptive or compensatory or of little functional significance? 
 
Techniques of Transcranial Magnetic (TMS) were used to determine 1) if clinical 
asymmetry of early PD is reflected in hemispheric asymmetry of sensorimotor 
cortical plasticity and intracortical inhibition, and 2) how these 
electrophysiological measures change with disease progression. 
We found that the hemisphere contralateral to the less affected side had 
preserved intracortical inhibition and a larger response to the plasticity protocol, 
whereas on the more affected hemisphere these were reduced. We further 
demonstrated that the decline in asymmetry of these measures correlated with 
the reduction in asymmetry of clinical symptoms, suggesting these were 
compensatory changes. 
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In dystonia patients, we investigated using TMS 1) if change of afferent input 
induced by botulinum toxin injections may change response to plasticity 
protocol in primary dystonia, and if 2) secondary and primary dystonia patients 
share the same pattern of electrophysiological abnormalities. 
We demonstrated that sensorimotor cortical plasticity in primary dystonia is not 
permanent abnormality but may be transitory reduced with botulinum injections 
treatment. Secondary dystonia patients, as opposed to primary dystonia 
patients did not have enhanced sensorimotor plasticity or impaired cerebellar 
function. We provide evidence that different types of dystonia do not necessarily 
have the same neuroanatomical substrates, which might have therapeutic 
implications. 
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THESIS OVERVIEW 
 
Through the series of TMS experiments detailed in Chapters 3-6, this PhD 
thesis explores the pathophysiological aspects of sensorimotor cortical plasticity 
and other electrophysiologic measures in PD and dystonia. 
 
Chapter 1 introduces the concept of brain plasticity and discuss how changes in 
plasticity may be relevant not only as mechanisms for compensation of 
neurological symptoms, but also as mechanism that cause or contribute to 
disease. This chapter introduces the techniques of TMS which are used to 
investigate PD and dystonia and then critically reviews current knowledge on 
electrophysiological abnormalities in both diseases. 
 
Chapter 2 presents general methods used in the experiments described in 
Chapters 3-6. 
 
Chapter 3 presents the study in which the inherent model of the clinically 
asymmetry of PD was used to compare electrophysiological measures between 
the two hemispheres. Sensorimotor cortical plasticity and intracortical inhibition 
were compared between the more and less affected sides in drug-naïve 
clinically asymmetric PD patients. It was found that the less affected 
hemisphere had increased cortical plasticity and preserved intracortical 
inhibition, while these were decreased on the more affected side. 
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In chapter 4 the follow-up study of the same PD patients described in Chapter 3 
is presented, which aimed to define pathophysiological significance of functional 
cortical reorganisation in early PD. We investigated the relationship between the 
changes in electrophysiological measures and the progression of motor signs. 
Based on the results, we put forward the hypothesis that there is a 
compensatory role for increased sensorimotor cortical plasticity in the early 
stages of PD. 
 
Chapter 5 describes set of experiments in patients with primary dystonia, 
intended to explore whether or not the response to TMS plasticity protocol is 
affected by the manipulation of the afferent input with botulinum toxin (BT) 
injections. The study found that the plasticity response decreased with 
successful BT injections and then recovered as the injections wore off. We 
propose that modulation of sensory afferent input by BT injections triggered 
subsequent reorganization of the motor cortex representation of the hand 
muscles, resulting in reduced sensorimotor cortical plasticity. 
 
Chapter 6 presents the study in which we explored whether or not the primary 
dystonia and secondary dystonia (caused by basal ganglia lesions) share the 
same pattern of electrophysiological abnormalities. This study reveals that 
secondary dystonia patients have a normal response to experimental plasticity 
protocols as opposed to an enhanced response in primary dystonia patients. It 
also reveals differences in cerebellar functional involvement between primary 
and secondary dystonias. 
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Each of the experimental chapters 3-6 leads on to its own discussion regarding 
their relevance to previous work, study limitations and new insights into 
sensorimotor cortical plasticity which they provide. 
 
In the final chapter, the overall conclusions are drawn from the whole work. 
Ideas are made about the possible clinical applications of the presented findings 
and also regarding directions for further work in the field.  
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 Introduction Chapter 1
 
1.1. Brain plasticity 
 
Plasticity is a fundamental brain property retained throughout the lifespan, 
enabling the brain to modify its structure and function in response to learning 
and experience, aging, injury or chronic disease. It can be defined as an ability 
of a system to change in response to different external and internal stimuli and 
to remain in such a new state until the next event occurs. The concept of brain 
plasticity is essential to understand not only psychological brain functions such 
as memory, learning or acquisition of a new motor skill but also to understand 
the pathophysiology of common neuropsychiatric diseases (Pascual-Leone et 
al., 2005). 
 
1.1.1 Adaptive plasticity vs. maladaptive plasticity in brain disorders 
 
Brain plasticity is perhaps best described as the double edge sword with its 
potential beneficial and detrimental behavioural consequences. 
 
In the context of neurological diseases, plasticity may be regarded as adaptive if 
it helps recovery of impaired brain function. Adaptive brain plasticity mainly 
comes into play after acute brain events such as stroke, traumatic or perinatal 
brain injury or following sensory deprivation, when functional (and structural) 
brain reorganisation help in improving the neurological deficit. In the stroke 
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literature, “brain plasticity” usually encompasses all possible mechanisms of 
neuronal reorganisation following ischaemic injury. From anatomical to cellular 
level it includes: recruitment of pathways that are functionally homologous to, 
but anatomically distinct from the damaged ones (for example, non-pyramidal 
corticospinal pathways), reinforcement of existing but functionally silent synaptic 
connections (at the periphery of the damaged core), dendritic arborisation, 
formation of new synapses and increase of synaptic strength (Rossini et al., 
2003). One of the best known examples of adaptive plasticity after sensory 
deprivation is recovery of vision in children with acquired amblyopia caused by 
strabismus. Selection of visual input from one eye causes a loss of cortical 
synaptic connections assigned to the other eye. However, patching the opposite 
“healthy” eye leads to improved vision in the impaired eye if this is attempted 
within the period of maximal visual plasticity in the first decade of life (Johnston, 
2004). The recovery in vision is possible due to reorganization of connections 
within previously deprived visual cortex. 
 
Although the concept of adaptive plasticity has mainly been related to acute 
brain events, similar processes may have a role in chronic neurological 
diseases, where plasticity may be considered as adaptive if it compensates for 
symptoms or symptom progression. For example, in the preclinical stages of PD 
or Alzheimer dementia, compensatory processes may help postpone the 
emergence of motor signs or cognitive symptoms, respectively (Zigmond, 1997, 
Bezard et al., 2003). The assumption is that disease symptoms will first appear 
when the adaptive changes become insufficient to keep up with ongoing cell 
loss. Even in the symptomatic stage, when the disease continues to progress, 
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worsening of symptoms may be viewed as a “trade off” between the 
compensatory changes and the functional/structural consequences of 
neurodegeneration. 
In contrast, brain plasticity is regarded as maladaptive when it causes or 
contributes to disease symptoms and/or their progression. Maladaptive 
plasticity has been implicated in various neurodevelopmental disorders, 
psychiatric diseases and adult onset neurological diseases. For example, in 
children with autistic spectrum disorders, several lines of evidence including 
findings of TMS studies, point to altered plasticity as the mechanism by which 
motor and cognitive behaviours are affected in these patients (Enticott and 
Oberman, 2013). In schizophrenia, impairment of synaptic plasticity has been 
shown to be associated with impaired motor skill teaching (Daskalakis et al., 
2008). The opinions about the role of plasticity in Alzheimer dementia have 
been divided with some authors suggesting that alteration of synaptic plasticity 
antedate cognitive impairment and contribute to the maladaptive molecular 
cascade culminating in the manifestation of dementia (Pascual-Leone et al., 
2011). Finally, it is believed that abnormally enhanced motor cortex plasticity 
contributes to the pathophysiology of dystonia in such a way that a subtle 
abnormality of plasticity may make some individuals susceptible to dystonia if 
plastic changes are pushed to their extreme by frequent repetition of particular 
movements (Quartarone et al., 2003).  
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1.1.2 Proposed mechanism of synaptic plasticity 
 
Modulation of synaptic strength is believed to be a common mechanism of brain 
plasticity, shared between physiological forms of plasticity such as memory and 
learning and pathological forms of plasticity underlying neurological diseases. 
 
In 1949, Donald Hebb introduced a theory of modification of synaptic strength. 
In his postulate on the cellular basis for learning, Hebb stated that “when an 
axon of cell A is near enough to excite a cell B and repeatedly or persistently 
takes part in firing it, some growth process or metabolic change takes place in 
one or both cells such that A’s efficiency, as one of the cells firing B, is 
increased” (Hebb, 1949). According to Hebbian’s rule, repeated simultaneous 
activity in pre- and postsynaptic neuron results in an increase of synaptic 
efficacy, a process known as long term potentiation or LTP. Stent (1973) 
proposed an addition to Hebbian’s rule, considering that connections would 
weaken when a presynaptic neuron is active at the same time as the post 
synaptic neuron is inactive. The processes that decrease synaptic efficacy are 
referred to as long term depression or LTD.  Nowadays, these two postulates 
are epitomised in the rule of Spike Timing Dependent Plasticity (STDP) that 
appears to mediate some forms of experience-dependent plasticity in vivo.  In 
STDP, both the temporal order and the interval between pre- and postsynaptic 
spikes are important, so that LTP and LTD are induced when there are tight 
temporal correlations between the spikes of pre- and postsynaptic neurons This 
form of synaptic plasticity has been studied extensively in a range of models, 
including cultured neurons (Bi and Poo, 1998), cortical slice preparations 
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(Magee and Johnston, 1997) and intact animals (Jacob et al., 2007). In a typical 
STDP protocol, a synapse is activated by stimulating a presynaptic neuron (or 
presynaptic pathway) shortly before or shortly after making the postsynaptic 
neuron fire by injection of a short current pulse. This pairing is repeated 50-100 
times at a fixed frequency. A number of studies have confirmed the importance 
of the temporal order of pre- and postsynaptic spiking in synaptic modification 
(Magee and Johnston, 1997, Bi and Poo, 1998, Caporale and Dan, 2008). 
 
LTP can also be produced using high-frequency stimulation (HFS) of 
presynaptic afferents (Bliss and Lomo, 1973), whereas LTD may be produced 
by low- frequency stimulation (LFS) of presynaptic afferents. In brain slice 
preparations synaptic plasticity may be quantified as a change of field potential 
(FP) following experimental stimulation. For example, in a motor cortex slice, 
stimulating microelectrodes are placed in cortical layer II/II and FP ( which is 
analogue to excitatory post-synaptic potential) is recorded before and after the 
conditioning “plasticity” protocol. The change in the FP size is a measure of 
synaptic plasticity. 
 
1.1.2 Cellular mechanisms of synaptic plasticity 
 
At excitatory glutamatergic synapses, the induction of LTP by HFS and LTD by 
LFS both require the activation of N-methyl-d-aspartate (NMDA) receptors and 
a rise in the postsynaptic Ca2+ level (Malenka and Bear, 2004). The 
presynaptic activation causes glutamate release while postsynaptic 
depolarization causes removal of the Mg2+ block on NMDA receptors, these 
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two processes together allowing Ca2+ influx. The amount and time course of 
postsynaptic Ca2+ rise depend on the induction protocol: HFS leads to fast, 
large Ca2+ influx, whereas LFS leads to prolonged, modest Ca2+ rise (Luscher 
and Malenka, 2012). In the Ca2+ hypothesis these two types of Ca2+ signals 
cause the activation of separate molecular pathways. Activation of 
Ca2+/calmodulin-dependent protein kinase II by a large Ca2+ rise is required 
for LTP, whereas recruitment of phosphatases such as protein phosphatase 1 
and calcineurin by a modest Ca2+ increase is the basis for LTD (Luscher and 
Malenka, 2012). 
 
Spike timing–dependent LTP and LTD also depend on NMDA receptor 
activation and the rise in postsynaptic Ca2+ level. However, LTP and LTD are 
not universal phenomena as the rules may differ in their details from one cell to 
another. Even at a single synapse, LTP produced by different patterns of 
stimulation may not be the same. In addition plasticity may also occur  at striatal 
metabotropic receptors (Gubellini et al., 2004), AMPA receptors and there may 
also be plasticity at GABA synapses (Maffei, 2011). 
 
1.2 Probing and measuring plasticity “in vivo” 
 
Plasticity changes in humans are best demonstrated through behavioural 
changes (for example using learning and memory tasks), but may also be 
captured using neuroimaging and electrophysiological techniques. For instance, 
changes in functional activity and anatomical connectivity may be demonstrated 
with neuroimaging techniques, but it should be noted that imaging will reveal 
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presumable anatomical or functional consequences of brain plasticity, rather 
than directly probing the mechanisms of plasticity. More direct measures of 
synaptic plasticity in humans in vivo are obtained using TMS, when TMS is 
applied as a plastic force and the brain tendency to undergo plastic changes is 
then quantified. 
 
1.2.1 Transcranial magnetic stimulation: magnetic induction as a non-
invasive way to electrically stimulate the brain 
 
The first attempts to electrically stimulate the human brain through intact scalp 
were made by Gualtierotti and Paterson (1954). They applied trains of stimuli 
over the scalp to induce motor responses in the contralateral limb. With their 
technique most of the current was lost by spreading through the scalp and only 
a small fraction reached the brain, resulting in painful and non-efficacious 
stimulation.  Merton and Morton (1980) later introduced clinically more feasible 
method of transcranial electrical stimulation.  They used a single high-voltage 
electrical pulses rather than a train of smaller pulses, which resulted in better 
penetration of the electrical current into the brain and relatively smaller current 
flow through the scalp, thus giving a more efficacious cortical stimulus. With this 
technique, stimulation over the motor cortex produced a twitch of contralateral 
body muscles and stimulation of visual cortex produced phosphenes. However, 
the pain was still strong enough to prevent wider clinical use. Finally, Barker et 
al. (1985) developed TMS, a technique for non-invasive and relatively painless 
stimulation of human motor cortex. Since then, TMS has been used extensively 
to study motor control in health and disease. 
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TMS relies on the principle of electromagnetic induction. A brief electrical 
current is passed through an insulated coil of wires placed over the scalp. This 
current generates a brief transient magnetic field running perpendicularly to the 
coil. Due to the low impedance of the scalp, skull and meninges, the magnetic 
field passes readily and without causing pain into the brain where it induces 
electric currents within the cortex. This induced electric current then activates 
cortical elements, resulting in an action potential or excitatory postsynaptic 
potential. In the motor cortex, a TMS pulse may activate corticospinal neurons 
directly, producing a “direct” volley of impulses in corticospinal axons ( “D” 
‘wave ) or more commonly indirectly through transynaptic connections with 
cortical interneurons , producing an “indirect “volley of impulses( “I”‘ waves )(Di 
Lazzaro et al., 2004). The descending volley of action potentials in the 
corticopinal tract triggered by TMS ultimately activates target muscles. This can 
be seen as a muscle twitch and is detected by electromyography (EMG) as a 
motor evoked potential (MEP). Thus, when TMS is given over the motor cortex, 
the amplitude of the MEP is an indirect measure of motor cortex excitability. 
Similarly, the change in the MEP after applying a TMS plasticity inducing 
protocol is used as a measure of synaptic plasticity in the motor cortex. 
 
When a figure-of-eight coil is held in such a direction that the TMS pulse causes 
electrical current to flow in a posterior-anterior direction perpendicular to the 
central sulcus, then corticospinal neurons are activated transynaptically and 
with a lower threshold. This propensity of TMS to activate corticospinal neurons 
transynaptically means that the response to TMS will depend on the level of 
excitability of cortical neurons at the time of stimulation. Indeed, it is this 
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tendency for transynaptic activation of corticospinal neurons that makes TMS a 
suitable technique for testing the excitability of intracortical synapses before and 
after experimental plasticity protocols. 
 
1.2.2 TMS measures of corticospinal excitability: Motor thresholds and 
Input-output curve 
 
The intensity of stimulation is expressed as a percentage of maximum 
stimulator output which may be adjusted in 1% gradations up to 100%. This 
allows for quantitative definition of corticospinal excitability in terms of the motor 
threshold (MT), which is defined as the lowest stimulus intensity (SI) at which 
MEP can be recorded in the target muscle. Thus, MT is expressed as a 
percentage of the maximal stimulator output and can be measured from relaxed 
muscle (resting motor threshold-RMT) or voluntary preactivated muscles (active 
motor threshold-AMT). 
 
With increasing SI, MEP amplitude increases, allowing for the assessment of 
“Input-Output” (IO) curve. IO curve thus describes a relationship between 
intensity of stimulation and amplitude of MEPs. While MT gives information 
about the most excitable neurons in the representation of the target muscle, the 
IO curve assesses less excitable neurons, which will be activated with higher SI 
( neurones with a higher threshold for firing) and those more distant from the 
centre of the TMS coil (Hallett et al., 1999)  . In healthy subjects, the shape of 
IO curve is approximately sigmoidal and its main features are steepness and 
plateau level. 
 30 
1.2.3 TMS measures of intracortical inhibition and facilitation 
 
The excitability of different intracortical interneurons within the primary motor 
cortex (M1) may be probed using TMS paired pulse techniques. Paired pulse 
experiments involve applying two stimuli, the test stimulus and the conditioning 
stimulus, separated in time by a varying interstimulus interval (ISI). If a 
suprathreshold test stimulus over M1 is preceded by a conditioning stimulus 
over the same cortical area, intracortical inhibition or facilitation may be tested, 
depending on ISI. The explanation is that the conditioning stimulus activates 
inhibitory or excitatory interneurons synapsing with corticospinal neurons and, 
depending on the ISI and on the intensity of the conditioning stimulus, the test 
response is either inhibited or facilitated. Several measurements of intracortical 
inhibition and facilitation can be probed using paired-pulses techniques, 
including short interval intracortical inhibition (SICI), intracortical facilitation 
(ICF), and long interval intracortical facilitation (LICI). TMS paired-pulse 
techniques thus allow the testing of the functional state of different types of 
intracortical interneurons. Cortical inhibitory and excitatory phenomena are 
subserved by different pools of interneurons: SICI is likely mediated by GABAa 
(Ziemann et al., 1996), ICF by NMDA (Ziemann et al., 1998c) and LICI by 
GABAb receptors (Werhahn et al., 1999). 
 
Cortical silent period (CSP) is another measure of intracortical inhibition. When 
a TMS stimulus is delivered during voluntary contraction of a target muscle, a 
period of EMG silence follows the MEP (Calancie et al., 1987). Although spinal 
inhibitory mechanism may contribute to the early part of the cortical silent period 
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(up to its first 50 ms of duration), the later part is generated within the inhibitory 
circuits of the motor cortex. CSP is presumably   mediated through GABAb 
receptors (Ziemann, 2004). 
 
1.2.4 TMS as experimental plastic force 
 
If the train of repeated TMS pulses is given over the target cortical area for a 
period of time (repetitive or rTMS), it is possible to induce changes in cortical 
excitability that outlast the period of stimulation and these are considered to 
reflect brain plasticity. If rTMS is used over the M1, the measure of plasticity is 
the change in MEP size that occurs after stimulation and that outlast the period 
of stimulation for minutes to hours. As a general rule, high frequency stimulation 
protocols (5 Hz and above)  are excitatory, producing an increase in 
corticospinal excitability, while low frequency protocols (1-5 Hz) are inhibitory, 
resulting in a decrease of corticospinal excitability (Ziemann et al., 2008). 
The major limitation of high frequency excitatory TMS protocols is in their 
potential for triggering epileptic seizures, especially if frequencies of 20 Hz and 
above are used (Wassermann et al., 1996). This issue is relevant, given that 
much higher frequencies (in the range 50-100 Hz) are used in brain slices for 
LTP induction. A number of other experimental TMS plasticity protocols have 
been invented to by-pass the problem of high frequency stimulation. The one 
that has been extensively used previously in both PD and dystonia and that I 
have used consistently through my work is paired associative stimulation (PAS). 
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1.2.5 Paired associative stimulation 
 
The PAS comprise of repeated pairing of sensory afferent stimulus with TMS 
stimulus and relies on the principle of sensorimotor integration within the M1. 
Stimulation of M1 with TMS activates corticospinal neurons trans-synaptically 
via interneurons (Di Lazzaro et al., 2004) .The same corticospinal neurons or 
the interneurons within the same microcolumn projecting onto corticospinal 
neurons receive somatosensory input (at short latency and with high 
topographical specificity ) via afferents from the somatosensory cortex (Rosen 
and Asanuma, 1972). Repeated pairing of a TMS stimulus over the cortical 
representation of the target muscle and an afferent stimulus evoked by 
electrical stimulation of the mixed peripheral nerve supplying the same target 
muscle may induce plastic changes, if the pairing of pulses converges on the 
corticospinal neurons in a precisely timed fashion (Muller-Dahlhaus et al., 
2010). In the original experiment , PAS consisted of electrical stimulation of the 
median nerve at the wrist and a TMS stimulus over the hot spot for the APB 
muscle in the contralateral M1, with median nerve stimulation preceding  TMS 
at an ISI of 25 ms (PAS25) (Stefan et al., 2000). This interval was chosen on 
the basis that the first component (N20) of the median nerve somatosensory-
evoked potential arrives in the primary somatosensory cortex typically at around 
20 ms (Allison et al., 1991) with a few extra milliseconds added on to allow for 
the afferent signal to be relayed from S1 to M1. Thus, the afferent signal evoked 
by median nerve electrical stimulation arrives in M1 synchronously, or shortly 
before transanssynaptic excitation of corticospinal neurons by the TMS pulse. 
The intensity of median nerve electrical stimulation was three times the 
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perceptual sensory threshold, while TMS intensity was adjusted to evoke MEPs 
of approximately 1 mV peak-to-peak amplitude. 90 pairs of median nerve 
electrical stimulation and TMS were given at a frequency of 0.05 Hz, the 
protocol lasting 30 minutes. Several modifications to this original protocol have 
been introduced, consisting of increased frequency of stimulation, with an aim 
to reduce the duration of stimulation. A rapid-rate paired associative stimulation 
introduced by Quartarone (2006a) is a variant of PAS with pairing of pulses at a 
rate of 5 Hz. Due to the higher frequency of stimulation, this protocol is shorten 
to only 2 min.   
 
In a typical PAS experiment, the excitability of the hand motor area is first 
probed by single TMS pulses over the “hot spot” for a chosen muscle and 1-mV 
MEPs are recorded. PAS is then delivered. The measure of plasticity is the 
change in 1mV-MEP size when probed using the same TMS intensity as given 
before PAS. The PAS induced plasticity lasts for at least 30–60 min and shows 
a characteristic topographical specificity to the muscles innervated by the 
stimulated peripheral nerve (Stefan et al., 2000). The exact timing of the 
afferent pulses and TMS pulses is important in determining the direction of 
changes of cortical excitability. MEP amplitudes increase when TMS activation 
of corticospinal neurons follows activation of same neural elements by afferent 
stimulus after a few milliseconds. If however, the afferent stimulus arrives later 
than TMS stimulus, a reversal of the effect occurs. If an ISI of 10 ms (PAS10) is 
used, this results in depression of MEPs (Wolters et al., 2003). Thus, PAS is 
considered to be a non-invasive brain stimulation paradigm that probes STDP. 
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1.2.6 Between-subject and within-subject variability of TMS measures 
 
It should be noted that even in neurologically normal subjects, there is variability 
in the neurophysiological and behavioural response to brain stimulation 
protocols (between-subject variability). As opposed to SICI which shows 
significant variability in the same subjects on repeated testing (within-subject 
variability) (Wassermann, 2002), the within-subject variability of the CSP is low, 
typically less than 10 % (Kukowski and Haug, 1992, Orth and Rothwell, 2004). 
This implies that longitudinal measurements of the CSP may be a sensitive 
electrophysiological marker of disease progression.  
 
Regarding PAS, the number of non-responder among healthy subjects  is 
considered to be between 25 and 40% (Stefan et al., 2004, Stinear and Hornby, 
2005, Fratello et al., 2006, Muller-Dahlhaus et al., 2008).The cause of this 
variability, although not completely understood, is thought to be genetically 
determined (Missitzi et al., 2011) but also depends on other factors, including 
attention, the subjects age and hormonal levels.(Stefan et al., 2002, Inghilleri et 
al., 2004, Muller-Dahlhaus et al., 2008, Sale et al., 2008). However, there is 
much less quantitative data on the reproducibility of the PAS effect in the same 
subjects on repeated testing (Fratello et al., 2006, Sale et al., 2007). Although 
observations from these few studies have not been conclusive, the within-
subject variability seems to be lower than between-subject variability. This is 
also suggested by the fact that the same “responders” are typically repeatedly 
selected for different studies as noted in several papers (Stefan et al., 2004, 
Sale et al., 2007). 
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1.2.7 Interhemispheric balance of TMS measures 
 
It is important to note for the purpose of the studies presented here, that  
healthy subjects show  no significant interhemispheric differences in TMS 
parameters of baseline corticospinal excitability such as MTs, IO curves; 
measures of intracortical inhibition and response to PAS protocol (Cicinelli et 
al., 1997, Priori et al., 1999, Ridding and Flavel, 2006). Therefore, these TMS 
measures may serve as sensitive markers of lateralised cortical pathology. 
 
1.3 The contribution of TMS in revealing pathophysiology of 
Parkinson’s disease and dystonia 
 
PD and dystonia are BG diseases, with opposed clinical manifestation of 
hypokinetic and hyperkinetic movement disorder, respectively. Both diseases 
arise as a consequence of abnormal (disease specific) BG output, which 
through the thalamus reaches the motor cortex, thus affecting the motor 
commands for muscle activation in simple and complex movements. The BG 
are deep structures and as such are inaccessible for non-invasive recordings. 
Considerable knowledge of the pathophysiology of both diseases has been 
gained by recording from circuits that are under direct or indirect control of the 
BG, but are reachable for conventional recording techniques. In particular, TMS 
has gained momentum in studying cortical pathophysiology related to BG 
diseases. This is conceivable because the motor cortex gives a final output for 
all voluntary and most involuntary movements, being under the influence of 
convergent inputs from the BG, cerebellum and peripheral afferents. 
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Electrophysiological changes at cortical, brainstem and spinal cord level and 
within cerebellar circuits have been described in PD and dystonia. Although 
these have contributed to our understanding of the pathophysiology of both 
diseases, it is somewhat surprising that these two disorders commonly share 
the same pattern of electrophysiological abnormalities, even though they are at 
opposite ends of the spectrum of movement disorders, with PD having “too 
little” and dystonia “too much “movement. For example, decreased intracortical 
inhibition (Ridding et al., 1995a, Ridding et al., 1995b) is present in both PD and 
dystonia. This unexpected pathophysiological likeness between the two quite 
distinct diseases raises a few important issues regarding the pathophysiological 
significance of the abnormal electrophysiological findings in circuits under the 
control of the BG. 
 
1.3.1 The significance of electrophysiological abnormalities in BG 
disease: Cause or consequence? Help or hindrance? 
 
Firstly, there is an issue regarding the causal relationship between presence of 
electrophysiological abnormalities and clinical symptoms. This problem may be 
summarised in the  following question: Is a certain electrophysiological finding 
the cause of a specific symptom or it is a consequence, or  is there no relevant 
association between the two? For example, in dystonia, decreased intracortical 
inhibition (and reduced inhibition at brainstem and spinal cord level) may be 
responsible for some dystonic symptoms such as co-contraction of antagonistic 
muscles, loss of selectivity in performing independent movements and overflow 
of dystonia. Alternately, decreased intracortical inhibition might be a 
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consequence of maintaining a dystonic posture that could, through abnormal 
afferent input, have resulted in cortical reorganisation. Finally, neither of two 
interpretations may be true. Reduced inhibition is also present  in  parts of the 
body that are not affected by dystonia, and in other neurological diseases that 
do not feature dystonia. This suggests that changes in intracortical inhibition 
may represent a non-specific functional change triggered by an abnormal BG 
output irrespective of the underlying disease. In other words, reduced inhibition 
seems to be a common pattern of cortical and subcortical reorganisation that 
occurs when these structures are under the influence of a distorted output from 
the BG. 
 
Assuming that clinical symptoms and changes in particular electrophysiological 
measures are related, the next important question is whether a particular 
electrophysiological abnormality represents a maladaptive change that 
contributes to the disease process, or a compensatory change that helps 
prevent emergence of the motor sign? Defining the pathophysiological 
significance of different cortical abnormalities in different types of movement 
disorder may be relevant for potential  treatments, so as to determine in which 
direction to intervene, to alleviate symptoms or even to slow down  disease 
progression. If changes are compensatory and help prevent motor symptoms 
emerging, then one might attempt to intervene to further enhance these 
changes. On the contrary, if changes are maladaptive, thus contributing to 
clinical symptoms and/or heralding disease progression, then it would be  useful 
to intervene in an attempt to diminish such  processes. This goal might be 
achieved by using non-invasive brain stimulation techniques. 
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With the rapidly increasing number of electrophysiological studies in PD and 
dystonia, it is becoming apparent that changes in the electrophysiological 
measures, such as corticospinal excitability and intracortical inhibition, are not 
specific to the disease, but rather reflect a limited repertoire of cortical “reaction” 
in the  face of an abnormal BG output. In the  hope of finding an 
electrophysiological marker that would be more predictive of the underlying 
disease, a focus of TMS research in BG diseases has switched to studies of 
brain plasticity. 
 
1.3.2 Cortical abnormalities in PD as revealed by TMS and their 
interpretation 
 
PD is characterised by cardinal motor symptoms of bradykinesia, rigidity and 
tremor. The main pathological substrate is dopamine cells death in the 
substantia nigra pars compacta with  consequent striatal denervation. Although 
the main pathological burden is within the nigrostriatal system, functional 
changes arise also in the structures downstream from the striatum, including the 
motor cortex, as a consequence of an abnormal BG output (Obeso et al., 2008). 
A second source of cortical dysfunction is reduced dopaminergic projections 
from the midbrain directly to the motor cortex (Gaspar et al., 1991). Treatments 
with L-DOPA or dopamine receptor agonists successfully relieve the motor 
symptoms of PD, but this can become complicated by motor fluctuations and 
dyskinesias during the course of disease. Deep brain stimulation (DBS) of the 
subthalamic nucleus or the internal globus pallidus (GPi) improve motor 
symptoms even in  patients with advanced disease including motor 
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complications, but the surgical approach is limited by many contraindications to 
surgery and the risk of  surgical complications. Studying the motor cortex 
involvement in PD and its relationship to the motor symptoms may reveal 
functional reorganisation that occurs in the face of dopamine loss  and thus may 
have treatment implications, given the accessibility of the motor cortex to non-
invasive brain stimulation techniques. Defining the mechanisms of sensorimotor 
cortex reorganisation may thus be helpful for building the most appropriate non-
invasive brain stimulation protocols with view to treating motor symptoms of PD. 
 
In trying to understand how the abnormal BG output in PD causes the cardinal 
motor symptoms, the motor cortex has been increasingly investigated. Indeed, 
different aspects of motor cortex function as revealed by TMS are found to be 
abnormal in PD and are discussed below: 
 
Motor thresholds and IO curve in PD 
 
While there is no difference between PD patients and healthy controls in simple 
measures of corticospinal excitability, such as RMT or AMT (Ueki et al., 2006), 
IO curves are steeper in patients comparing to controls (Valls-Sole et al., 1994, 
Chen et al., 2001). This is thought to be an expression of increased 
corticospinal excitability in PD. However, a difficulty with this interpretation is 
that background muscle activity itself influences the size of MEP for a given 
stimulus intensity. Therefore, it may be that the steeper IO curve represents a 
confounding effect of rigidity rather than increased cortical excitability. 
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Intracortical inhibition in PD 
 
Several measured of intracortical inhibition are also impaired in PD.  For 
example, shortening of CSP comparing to controls has been repeatedly 
reported (Priori et al., 1994, Nakashima et al., 1995, Berardelli et al., 1996, 
Manfredi et al., 1998). CSP is shorten in the hemisphere contralateral to the 
clinically more affected side compared to the less affected side in early 
asymmetric PD patients (Cantello et al., 2007) and dopaminergic medications 
prolong/ normalize the CSP, providing the evidence that the deficit in the CSP is 
dopamine related. 
 
SICI is also reduced in PD patients when they are tested “off” dopaminergic 
medications (Ridding et al., 1995a), with this abnormality being present from the 
early stages of the disease (Buhmann et al., 2004). There is still ongoing debate 
about the exact cortical origin of the reduced SICI in PD. Some authors suggest 
that a decreased SICI reflects decreased threshold of excitatory neurons 
mediating intracortical facilitation (MacKinnon et al., 2005, Ni et al., 2013), while 
the classic view is that SICI reflect dysfunction of inhibitory GABAa 
interneurons. 
 
The interpretation of the functional significance of reduced intracortical inhibition 
in PD is not straightforward. A classical view is that deficient inhibition is an 
indirect expression of the dopaminergic deficit which, by distorting BG output, 
affects the motor cortex (Ridding et al., 1995a). An alternative hypothesis is that 
reduced cortical inhibition serves as a compensation for bradykinesia (Cunic et 
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al., 2002). For example, in healthy subjects SICI is reduced during voluntary 
muscle contraction (Ridding et al., 1995c), and even prior to the onset of 
movement (Reynolds and Ashby, 1999). Accordingly, in PD reduced SICI at 
rest may serve to facilitate the initiation of movement, representing an adaptive 
motor strategy that compensates for slowness of movement 
. 
Plasticity in Parkinson’s disease 
 
Dopaminergic deficit is clearly related to abnormal plasticity mechanisms at 
corticostriatal synapses in animal models of PD. In the 6-hydroxydopamine 
parkinsonian rat, complete dopaminergic denervation decreases both LTP and 
LTD, while incomplete dopaminergic selectively affects LTP in corticostriatal 
synapses.  While it has not been possible to test for plasticity changes in 
corticostriatal synapses in vivo in PD patients, plasticity of the sensorimotor 
cortex has been extensively investigated. This was found to be abnormally 
reduced and even absent in advanced PD patients when tested “off” 
dopaminergic treatment (Morgante et al., 2006, Ueki et al., 2006, Suppa et al., 
2011, Kacar et al., 2012, Kishore et al. 2012) , suggesting widespread 
functional abnormalities that  are not confined to the BG . Dopamine plays a key 
role in the modulation of mechanisms of synaptic plasticity, therefore it is not 
surprising that the response to an experimental plasticity protocol recovers with 
dopaminergic treatment (Morgante et al., 2006, Ueki et al., 2006). Reduced 
motor cortex plasticity may be the consequence of dopamine loss within 
nigrostriatal system, that via abnormal BG output affect the cortex, or it may be 
a result of the dopaminergic deficit within M1. However, it should be noted that 
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not all studies reported abnormally reduced plasticity in PD. For example, 
Bagnato et al. (2006) reported increased plasticity in the sensorimotor cortex in 
PD patients, namely a stronger PAS-induced increase of the MEP amplitude 
with a spread of the PAS effect in to non-target muscles compared to a healthy 
control group. In this study, PAS response normalised when patients were 
retested “on” medications. These apparently contradicting findings suggest that 
the motor cortex may undergo various stages of functional reorganisation, 
rather than being in a fixed disease- predetermined state. 
 
Maladaptive plasticity at corticostriatal synapses has been implicated also in the 
genesis of Levodopa induced dyskinesias. Depotentiation is a form of synaptic 
plasticity that implies a reversal of established LTP by a low-frequency 
stimulation protocol and also depends on dopaminergic signalling.  
Depotentiation is absent in corticostriatal synapses in an experimental model of 
l-DOPA-induced dyskinesias (Picconi et al., 2003). Similarly, dyksinetic but not 
non-dyskinetic PD patients have impaired depotentiation in the M1, again 
probably reflecting abnormal mechanisms of synaptic plasticity that generalises 
across the whole BG-thalamo-cortical circuit (Huang et al., 2011). 
 
In summary, PD is traditionally understood as a disorder with reduced motor 
cortex plasticity. Even though considerable experimental evidence suggests 
that this is the case in advanced PD, preclinical stages and patients in early 
stages of disease have been much less investigated. If symptoms of 
neurodegenerative diseases are regarded as a trade-off between compensatory 
mechanisms and irreversible cell loss, it is possible that changes in plasticity in 
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PD reflect a dynamic process, that may initially have a compensatory role, while 
later becoming ineffective or even maladaptive. 
 
1.3.3 Cortical abnormalities in dystonia as revealed by TMS and their 
interpretation 
 
Dystonia is a hyperkinetic movement disorder, featuring repetitive twisting 
movements and sustained abnormal postures of affected parts of the body. 
Dystonia is classically thought to be a basal ganglia disorder and there are 
several lines of evidence to support this: (i) Lesions of the BG and its 
connections may cause dystonia. (ii) Abnormal activity or subtle changes in BG 
structure have been demonstrated in primary dystonia using different imaging 
techniques. (iii) Dystonia often occurs in other BG diseases or may be the main 
symptom of nigrostriatal dysfunction, i.e.  acute dystonic reaction and tardive 
dystonia. (iv) Finally, dystonic symptoms may be cured or significantly improved 
with DBS. 
 
However, there are a limited number of experimental studies including 
electrophysiological recordings from BG structures, the reason being the 
relative rarity of the disease and the invasive nature of such studies. Therefore, 
only patients undergoing deep brain stimulation surgery have been studied 
(Vitek et al., 1999, Zhuang et al., 2004, Starr et al., 2005, Tang et al., 2007). 
Another source of information on abnormal motor control in dystonia was 
gathered from electrophysiological studies that involved the cortex, brainstem, 
spinal cord and recently, cerebellum.  
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Loss of inhibition in dystonia 
 
A consistent finding across neurophysiological studies in dystonia has been a 
loss of inhibition at different CNS levels, including spinal cord, brainstem and 
motor cortex (Berardelli et al., 1985, Nakashima et al., 1989, Ridding et al., 
1995b). It seems logical to relate the loss of inhibition to some dystonic 
manifestations such as non-selective and prolonged muscle contraction. 
However, deficient inhibition cannot be the sufficient explanation for the genesis 
of dystonic symptoms, because the same abnormality is also present in parts of 
the body not affected by dystonia (Sommer et al., 2002), in clinically unaffected 
carriers of DYT1 mutations (Edwards et al., 2003), in other hyperkinetic 
movement disorders such as tics (Ziemann et al., 1997) and even in hypokinetic 
movement disorders such as PD (Ridding et al., 1995a). 
 
Plasticity in dystonia 
 
Maladaptive sensorimotor cortical plasticity has been put forward as one of the 
major pathophysiological features of dystonia (Quartarone and Pisani, 2011). It 
has been showed that patients with primary dystonia have enhanced response 
to different experimental plasticity protocols (Quartarone et al., 2003, Edwards 
et al., 2006, Weise et al., 2006, Tamura et al., 2009). In the initial study on PAS 
response in writer’s cramp, patients had two main abnormalities. Firstly, the 
PAS response was enhanced in the target APB muscle comparing to controls 
and secondly, there was a loss of topographic specificity in patients, with an 
increase of MEP in the non-target FDI muscle after PAS that was not present in 
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healthy participants (Quartarone et al., 2003). Yet, not all studies reported an 
increased response to PAS in primary dystonia patients (Meunier et al., 2012). 
Another way to look at plasticity changes is by indirect mapping of sensory and 
motor cortices, using TMS or functional imaging. In patients with primary 
dystonias, mapping studies showed enlargement of sensory receptive fields and 
blurring of margins of motor maps with overlap between representations of 
adjacent muscles (Thickbroom et al., 2003). 
 
An important feature that may link the role of maladaptive plasticity to 
development of dystonic symptoms is that focal limb dystonia is typically 
triggered by a period of intensive training of a particular movement. In a monkey 
model of dystonia, overtraining in specific hand movements may also trigger the 
appearance of symptoms that resemble human dystonia (Byl et al., 1996). The 
somatosensory cortex of these animals undergoes functional reorganisation, 
resulting in enlargement and overlapping of receptive fields of individual digits. 
The idea is that overtraining itself triggers functional changes in sensory and 
motor cortices, leading to abnormal sensorimotor integration that somehow 
results in dystonic symptoms. However, an important question is why only some 
human subjects develop dystonia after excessive training whereas others do 
not. The answer might be in the two- hit hypothesis, which suggests that 
dystonia develops when use-dependent environmental factors coexist with 
inherently abnormal mechanisms of plasticity within the sensorimotor cortex. 
Thus, abnormal sensorimotor cortex plasticity may have  a role in the 
pathophysiology of dystonia, so that individuals with an excessive tendency to 
form an association between sensory input and motor output may develop 
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symptoms if plastic changes are pushed to an extreme by frequent repetition of 
movement (Quartarone and Pisani, 2011). 
 
However, it should be noted that the two-hit explanation account only for task-
specific primary dystonias, as it doesn’t consider other forms dystonia in which 
there is no obvious role for over-training of the affected body parts. These 
include other focal and generalised primary dystonias or secondary dystonias. It 
might be possible that in these other forms of dystonia abnormalities of the 
plasticity mechanisms coexist with other factors that may trigger dystonia, for 
example BG lesions in the case of stroke or perinatal injury, neuroleptic drug 
use in the case of drug induced dystonia or still unknown environmental factors 
in the case of primary dystonias that are not task specific. Alternatively, 
enhanced mechanism of synaptic plasticity might be a trait specific for primary 
dystonia only. 
 
Finally, distorted plasticity is also present  in cortical representations of the body 
parts that are not affected by dystonia (Quartarone et al., 2008) and in 
professional musicians who do not develop occupational dystonias (Rosenkranz 
et al., 2007),  further complicating the issue of pathophysiological significance of 
abnormal plasticity in primary dystonias. 
 
In summary, it has been traditionally understood that enhanced motor cortex 
plasticity represented a maladaptive trait for the development of dystonic 
symptoms. While this might be the case in primary (including genetic forms) 
dystonias, increased plasticity might not be a feature of all dystonias. For 
 47 
example, patients with psychogenic dystonia have normal response to 
experimental plasticity protocols (Quartarone et al., 2009), while other forms of 
dystonia including secondary forms have not been hitherto investigated. Thus, 
there may be no uniform hypothesis to explain the pathophysiology of all 
dystonias, but rather, different forms of dystonia may have diverse 
pathophysiological backgrounds. 
 
Neuroanatomical network of dystonia 
 
Several studies have addressed the link between BG output and cortical, 
brainstem and spinal cord functional abnormalities, by investigating the changes 
in electrophysiological measures within these circuits following DBS of GPi in 
patients with primary dystonia. 
 
When abnormal BG output is modulated by DBS treatment, this  results in 
normalisation of previously reduced inhibition at different CNS levels (Tisch et 
al., 2006a, Tisch et al., 2006b)  and importantly the normalisation of 
sensorimotor cortical plasticity (Tisch et al., 2007, Ruge et al., 2011). 
 
In healthy subjects, the cerebellum modulates the extent and duration of the 
response to sensorimotor plasticity protocols, in such a way that cerebellar 
cortex excitation prevents the PAS  inducing a sensorimotor plasticity in the 
primary motor cortex (Hamada et al., 2012b, Popa et al., 2012), whereas there 
is some evidence that cerebellar cortex inhibition makes the PAS more efficient 
at inducing  plasticity (Popa et al., 2013). In patients with writer's cramp, 
 48 
cerebellar cortex excitation and inhibition are both ineffective in modulating 
sensorimotor plasticity, suggesting that  altered cerebellar processing of 
incoming afferent information  may result in maladjusted sensorimotor 
integration and consequently abnormal response to PAS in primary dystonia 
(Hubsch et al., 2013). 
 
There may also be a link between distorted afferent input and abnormal cortical 
plasticity in dystonia. For example, in focal limb dystonia altered hand cortical 
maps which are index of maladaptive cortical plasticity are normalised if afferent 
input is modified by botulinum toxin injections into dystonic muscles 
(Thickbroom et al., 2003). 
 
Dystonia may be thus be regarded as an abnormality of broad functional motor 
network, which apart from BG include sensorimotor cortex, sensory afferent 
input, the cerebellum, brainstem and spinal cord. The assumption is that 
abnormalities in sensorimotor cortical plasticity in dystonia should not be 
regarded as an independent fixed state, but rather as a dynamic functional 
reorganisation of motor cortex influenced by inputs from different nodes in the 
broad dystonia network. Furthermore, different types of dystonia might not 
necessary share the involvement of the same nodes in the dystonia network, 
but may rather have different neuroanatomical substrates. 
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1.4. Aim of the PhD study 
 
The aim of my PhD research was to gain further knowledge on significance of 
sensorimotor cortical plasticity changes (and other cortical electrophysiology 
measures) in PD and dystonia. I tried to achieve this by studying relationship 
between changes in these measures and changes in clinical manifestation of 
disease in PD and primary dystonia. In addition, I compared sensorimotor 
cortical plasticity and other electrophysiological measures between primary and 
secondary dystonia patients to see if different types of dystonia share the same 
neurophysiological pattern. 
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 General Methods Chapter 2
 
In all the work within this thesis, I have used TMS techniques to study 
corticospinal excitability, intracortical inhibition and sensorimotor cortical 
plasticity in PD patients, different group of dystonia patients and healthy 
participants. 
 
2.1. Participants 
 
PD patients and patients with primary and secondary dystonia were recruited 
from the Movement Disorder Outpatient Clinics at the National Hospital for 
Neurology and Neurosurgery in London and occasionally from the collaborating 
institution depending on the study (Sapienza University at Rome and University 
of Seville). Healthy participants were recruited from the list of healthy 
participants maintained by Movement Disorders Group of the Sobell 
Department of Motor Neuroscience and Movement Disorders. The exclusion 
criteria for all participants were in accordance to guidelines for use of repetitive 
TMS (rTMS) in research and included history of epileptic seizures and 
implanted metal device (Wassermann et al., 1996, Rossi et al., 2009). 
Demographic and clinical characteristics of the patients are given in 
experimental chapters (Chapters 3-6). 
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Written informed consent was obtained from all participants. All studies were 
approved by the local ethics committee and conducted in accordance with the 
Declaration of Helsinki. 
 
2.2. Electromyographic recordings 
 
Participants were seated comfortably in an armchair and were instructed to 
relax arm and hand muscles. EMG recordings were made from hand muscles:  
abductor pollicis brevis (APB) and first dorsal interossei (FDI) or abductor digiti 
minimi (ADM) muscles on the side contralateral to stimulated cortex. Ag-AgCl 
surface electrodes with a belly-tendon montage were used, with a ground 
electrode  placed over the wrist. The level of background EMG activity was 
monitored and trials with background EMG activity were rejected online. The 
background EMG area for at least the 200 ms preceding the TMS pulse was 
measured in all recorded trials and the EMG root mean square amplitude 
calculated to ensure comparability of the baseline activity across different 
experiments in patients (within-subjects) and between patients and healthy 
participants (between-subjects). EMG signals were amplified (1000x) and band-
pass filtered (bandwidth 20Hz to 2 kHz) with a Digitimer D360 amplifier 
(Digitimer, UK), acquired at a sampling rate of 5 kHz through a 1401 laboratory 
interface (Cambridge Electronic Design, Cambridge, UK) and stored on a PC. 
The EMG traces were analysed “off- line”, using customized Signal® software 
version 4.00.  
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2.3. Transcranial Magnetic Stimulation 
 
Single TMS pulses of the M1 were applied using Magstim 2002 magnetic 
stimulator with a monophasic current waveform (Magstim Company, 
Carmarthenshire, Wales, UK). For paired pulses techniques, two Magstim 2002 
stimulators were coupled via a Bistim module. Stimulators were connected to a 
standard figure-of-eight TMS coil (diameter 70 mm). The intersection of the coil 
was held over the “hotspot”, tangentially to the skull with the handle pointing 
backwards and laterally at an angle of ~45 degrees to the sagittal plane in order 
to generate a posterior–anterior current in the brain (Kaneko et al., 1996). The 
“hot spot” was marked on the participant’s head over the optimal scalp positions 
for eliciting MEPs of maximal amplitudes in the contralateral APB muscle. The 
same hot spot was used for assessing the MEPs in other muscles (Stefan et al., 
2000). 
 
2.3.1. Corticospinal excitability 
 
Active and resting motor threshold were determined according to the standard 
definitions (Rossini et al., 1994).  RMT was defined as the minimum intensity 
that evoked a peak-to-peak MEP of 50 μV in at least 5 out of 10 consecutive 
trials in the relaxed APB muscle. AMT was defined as the minimum intensity 
that elicited a reproducible MEP of at least 200 μV in the tonically contracting 
APB muscle in at least 5 out of 10 consecutive trials, while subject was 
performing contraction of ABP at approximately 10–15% of maximum voluntary 
contraction. 
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Single 1mV-MEPs were recorded using a SI adjusted to produce MEP of 
approximately 1 mV amplitude in the relaxed APB muscle and this intensity was 
kept constant for assessment of changes of 1mV-MEPs after PAS. IO curves 
were assessed by recording four MEPs at raising SI, increasing in 10% steps, 
as indicated in details in each experimental chapter. 
 
2.3.2. Intracortical inhibition 
 
SICI and ICF were assessed with paired-pulse paradigm (Kujirai et al., 1993). 
The intensity of the test stimulus was 1mV- MEPs intensity. In studies on PD 
patients described in chapters 3 and 4,  the intensity of the conditioning stimulus 
(CS) was 90% of RMT, an intensity known to produce a net loss of inhibition in 
PD (MacKinnon et al., 2005). In studies on dystonia patients (chapters 5 and 6), 
the intensity of CS was set at standard 80% of AMT. SICI and ICF were 
assessed at rest, using ISIs as indicated in each experimental chapter. For SICI 
and ICF 10 MEPs were collected for each ISI and for the test stimulus alone. 
For assessment of CSP, 20 single TMS pulses were applied at an intensity of 
120% RMT, while patients performed a constant contraction of APB at 20% of 
maximum voluntary contraction. 
 
2.4. Paired Associative Stimulation 
 
For studies described in chapters 3, 4 and 6, I used excitatory PAS protocol 
(PAS25), which consisted of 200 electrical stimuli to the median nerve at the 
wrist paired with TMS stimuli over the APB hot spot, given at the rate 0.25 Hz 
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(Ziemann et al., 2004). Each TMS stimulus was preceded by an electrical 
stimulus by 25 ms (ISI 25ms). Intensity of electrical stimulus was 300% of the 
perceptual threshold; while TMS intensity was adjusted to the intensity that 
produced 1mV-MEP in relaxed APB muscle. Median nerve electrical stimulation 
was applied through a bipolar electrode, with the cathode positioned proximally 
(Digitimer DS 7 stimulator; Digitimer Ltd, Welwyn Garden City, Herts, UK). The 
electrical pulses were constant current square wave pulses with a pulse width of 
200 µs.Subjects were instructed to look at their stimulated hand and to report 
every 20th peripheral electrical stimuli they perceived in order to ensure 
comparable attention levels between sessions. Number of errors in counting 
peripheral nerve stimuli was noted. In the study described in chapter 5, a rapid 
PAS (rPAS) protocol was used, with details explained in that chapter. In all 
experiments, to assess the effect of PAS (or rPAS) on 1mV-MEPs, 20 MEPs 
were recorded before PAS and at each time point after PAS. 
 
2.5 Statistical analysis 
 
Distribution of data was assessed using Shapiro–Wilk test of normality. 
Greenhouse-Geisser method was used where necessary to correct for non-
sphericity. When data were normally distributed, parametric tests (ANOVA) with 
post-hoc Tukey test were used. For non-normally distributed data and for 
ordinal data, non-parametric tests were used as described in the experimental 
chapters. The significance was pre-set at p ≤ 0.05. Unless otherwise stated, 
data are given as mean +/- standard error of the mean (SEM).  
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 Interhemispheric asymmetry in Chapter 3
sensorimotor cortical plasticity and 
intracortical inhibition in early Parkinson’s 
disease 
 
In the following set of experiments we studied if clinical asymmetry of the motor 
symptoms in early, drug- naïve PD patients is reflected in an asymmetry of 
cortical TMS measures. In the “model” of early asymmetric PD, the more 
affected side is in the more advanced stage of the disease, while less affected 
side is still asymptomatic or very mildly symptomatic, despite considerable 
dopaminergic loss even in the striatum corresponding to the less affected side. 
The hypothesis was that if there is any functional change that prevents motor 
symptom progression it is likely to be detected in the hemisphere contralateral 
to the less affected side. Thus, we compared the corticospinal excitability, 
intracortical excitability and sensorimotor cortical plasticity between the 
hemispheres contralateral to the clinically less and more affected side. 
 
The work presented in this Chapter was originally published in the form of a 
research article: Kojovic M, Bologna M, Kassavetis P, Murase N, Palomar FJ, 
Berardelli A, Rothwell JC, Edwards MJ, Bhatia KP. Functional reorganization of 
sensorimotor cortex in early Parkinson disease. Neurology. 2012 May 
1;78(18):1441-8. 
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3.1 Summary 
 
Several neurophysiological measures known to be abnormal in the M1 of 
patients with advanced PD were tested in the both hemispheres ( contralateral 
to the more and less affected side) of 16 newly diagnosed and drug naive PD 
patients and compared with 16 age-matched healthy participants. LTP-like 
effects were probed using a PAS protocol. We also measured SICI, ICF, CSP 
and IO curves. We found that the hemisphere contralateral to the less affected 
side had preserved intracortical inhibition and a larger response to the plasticity 
protocol than healthy participants. In the hemisphere contralateral to the more 
affected side, there was no response to the plasticity protocol and inhibition was 
reduced. There was no difference in the IO curves between sides or between 
PD patients and healthy participants. Increased sensorimotor cortical plasticity 
in the hemisphere contralateral to the less affected side is consistent with a 
functional reorganisation of the sensorimotor cortex and may represent a 
compensatory change that contributes to delaying the onset of clinical signs. 
Alternatively, it may reflect a maladaptive plasticity that provokes onset of the 
symptoms. As seen in the hemisphere contralateral to the more affected side, 
plasticity deteriorates as the symptoms progress. The rate of change in the 
interhemispheric difference of the PAS response over time could be developed 
into a surrogate marker of disease progression. 
 
3.2. Introduction 
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Motor signs in PD appear when striatal dopamine is depleted beyond the critical 
threshold of approximately 60-80 % (Lee et al., 2000). Neuropathological and 
neuroimaging evidence suggests that changes in the nigrostriatal system 
compensate for dopamine deficiency (Zigmond et al., 1990, Kaasinen et al., 
2000, Lee et al., 2000, McCallum et al., 2006, Appel-Cresswell et al., 2010, de 
la Fuente-Fernandez et al., 2011). However, given the extent of preclinical 
dopaminergic denervation (Tissingh et al., 1998), it is conceivable that 
compensatory changes extend beyond the nigrostriatal circuit. 
 
Clinically asymmetric PD patients represent a valuable model for studying 
compensatory reorganisation within the motor system since functional changes 
that prevent symptom progression may possibly be present in the hemisphere 
contralateral to the less affected side. A previous [18F]-fluorodeoxyglucose PET 
(FDG-PET) study provided little evidence that this might be the case (Tang et 
al., 2010). Asymmetric patients had an equally abnormal metabolic pattern in 
the cortex and subcortex of both hemispheres (except within the putamen) 
(Tang et al., 2010). However, an apparent absence of metabolic asymmetry in 
the sensorimotor cortex, a major output of basal ganglia-cortical loops, could 
reflect insufficient sensitivity of metabolic measures. 
 
In this study we measured the excitability of circuits in the sensorimotor cortex 
of clinically asymmetric drug naive PD patients with TMS techniques known to 
be sensitive to dopaminergic deficit. These involved PAS, a method that 
assesses long term potentiation LTP- like plasticity at cortical synapses (Stefan 
et al., 2000) and which relies on sensorimotor integration of afferent input and 
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motor output, that are known to be impaired in PD (Lewis and Byblow, 2002).  
In addition, we employed measures of intracortical inhibitory and excitatory 
function.  We compared these measures between the less and more affected 
hemispheres in the patients and we contrasted them with those of healthy 
participants. 
 
3.3 Methods 
 
3.3.1 Participants 
 
Sixteen newly diagnosed, drug naive patients with clinically asymmetric 
idiopathic PD (11men, 5 women, mean age 59 years, range 34-73 years) 
(Table 3.1) and sixteen age -matched healthy participants (11men, 5 women, 
mean age 60 years, range 35-73 years) were included in the study. Idiopathic 
PD was diagnosed according to the UK Parkinson’s Disease Society Brain 
Bank criteria (Hughes et al., 1992) and further confirmed by abnormal dopamine 
transporter (DAT) SPECT in all patients. Clinical disease severity was assessed 
with the motor section (items 3.1–3.18) of the MDS-UPDRS scale (Goetz et al., 
2008a). For the less and more affected side, the motor subscore was calculated 
from the sum of items 3.3 to 3.8 and 3.15 to 3.17 for each side (lateralised 
UPDRS score). None of the participants was on any medications that are 
known to affect the measurements performed. All participants were right-
handed.  
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 Table 3.1 Clinical and demographic characteristics of Parkinson's disease patients 
 
 
Abbreviations: UPDRS, Unified Parkinson’s Disease Rating Scale; M,male; F, female ; R, right;L, left
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3.2 EMG recordings and TMS 
 
Details are given in methodological chapter 2. EMG recordings were made from 
APB and ADM muscles. IO curves were assessed by recording four MEPs at 
each of ten stimulation intensities, increasing in 10% steps from 80% to 170% 
of RMT.SICI was assessed using ISIs of 2, 3 and 4 ms and ICF at ISI of 15 ms. 
 
3.3.3 Experimental design 
 
Patients were tested on both hemispheres, corresponding to the more and less 
affected side in two different TMS sessions, separated by a week. The order of 
the tested hemisphere (affected vs. unaffected) was randomised between 
subjects. Healthy participants were tested on the dominant hemisphere only, 
since there is no evidence of a difference in sensorimotor cortical plasticity and 
other TMS measures between the dominant and non-dominant hemisphere. In 
each session we measured RMT, AMT, 1mV MEP, IO curve, SICI, ICF and 
CSP. We then delivered PAS and assessed the effect of this conditioning 
protocol on corticospinal excitability (RMT, AMT and 1mV- MEPs) and CSP at 
three time points: 0, 15 min and 30 min after PAS (Figure 3.1). 
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Figure 3.1 Experimental design 
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3.3.4 Statistical analysis 
 
We used Wilcoxon’s signed-rank test to compare differences in the UPDRS 
scores between less and more affected side and to compare age between PD 
patients and healthy participants. Chi-square test was used to compare gender 
distribution between PD patients and healthy participants. The TMS parameters 
between the hemispheres of PD patients and healthy participants were 
compared using 2-way ANOVAs with a factor GROUP (less affected vs. more 
affected side vs. healthy participants) as a between-subject factor. For IO 
curves the factor STIMULUS INTENSITY (10 levels of stimulator output 
intensity) was used as within-subjects factor. For SICI, ISI (3 levels: normalised 
MEP size at 2, 3 and 4 ms) was used as a within-subject factor. PAS produced 
by stimulation of median nerve has different effects on MEPs evoked in median 
and non-median innervated muscles (Stefan et al., 2000). Thus the effects on 
MEPs in the APB and ADM muscles were evaluated in separate 2-way 
ANOVAs for each muscle with TIME (4 levels: before PAS and 0, 15 and 30 min 
after PAS) as a within-subject factor. The effect of PAS on CSP was evaluated 
using TIME (3 levels: normalised CSP duration at 0, 15 and 30 min after PAS) 
as a within-subject factor. Conditional on a significant F-value, to explore the 
strength of main effects and patterns of significant interactions we used post 
hoc Tukey HSD test and follow-up ANOVAs, respectively. Possible correlations 
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between clinical and demographic data and TMS measures were evaluated with 
Spearman correlation analysis. 
 
3.4. Results 
 
3.4.1 Clinical and demographical data 
 
No differences in age and gender distributions were found between PD patients 
and healthy participants. As expected, there was a significant difference in 
lateralised UPDRS scores between the less and more affected side in PD 
patients ( Table 3.1), due to higher scores on the more affected side (paired 
sample t-test, p< 10-3). 
 
3.4.2 Corticospinal excitability and EMG root mean square amplitude 
 
At baseline, there was no difference in RMT, AMT, 1mV MEPs or resting EMG 
root mean square between the hemispheres in PD patients or between patients 
and healthy participants. For IO curves ANOVA showed an expected effect of 
STIMULUS INTENSITY (F (9, 423) =73.4; p <10-3). Factor GROUP and the 
interaction GROUP X STIMULUS INTENSITY were non-significant, indicating 
no difference in baseline corticospinal excitability between the groups. 
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3.4.3 SICI 
 
ANOVA revealed a difference in SICI between groups (factor GROUP (2, 45) 
=6.28; p=0.004), due to overall reduced SICI in the hemisphere contralateral to 
the more affected side compared with the hemisphere contralateral to the less 
affected side (p=0.01) and with healthy participants (p=0.007) (Figure 3.2). 
There was no difference in SICI between the hemisphere contralateral to the 
less affected side and healthy participants. Factor ISI was also significant (F (2, 
90) =14.8; p <10-3), due to less SICI at 4 ms compared to 2 and 3 ms (p =10-3 
and p<10-3, respectively) across all 3 groups. (GROUP X ISI interaction was not 
significant). The correlation analysis  between lateralised UPDRS score and the 
averaged amount of  SICI at 2, 3 and 4  ms (expressed as a ratio to 
unconditioned MEP) revealed  that more severe symptoms were associated 
with greater reduction in SICI (R= 0.42; p=0.017) (Figure 3.3). 
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Figure 3.2 Short interval intracortical inhibition 
 
In PD patients SICI is preserved in the hemisphere contralateral to the less 
affected side and does not differ from SICI in healthy participants. In the 
hemisphere contralateral to the more affected side SICI is reduced. Data is 
plotted as a ratio to the unconditioned MEP amplitude. .   
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Figure 3.3 Correlation analysis between SICI and clinical severity of PD 
 
Averaged SICI (for ISI 2, 3 and 4ms, expressed as a ratio to the unconditioned 
MEP) positively correlates with lateralised UPDRS scores. A higher SICI ratio 
corresponds to less SICI and therefore a positive correlation indicates that the 
greater reduction in SICI is associated with more severe motor symptoms. Blue 
markers and red markers correspond to the values from the hemisphere 
contralateral to the less and more affected side, respectively. If values from less 
and more affected sides are plotted separately, there is however no significant 
correlation. (** p ≤0.01)  
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3.4.4 ICF 
 
For ICF, ANOVA revealed no group difference (F (2, 37) =0.56; p =0.94) 
(Figure 3.4). 
 
 
Figure 3.4 Intracortical facilitation at ISI 15 ms 
 
There is no difference in ICF between the hemispheres in PD patients or 
between patients and healthy participants. Data is plotted as a ratio to the 
unconditioned MEP amplitude.  
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3.4.5 CSP 
 
At baseline, ANOVA revealed differences in the CSP duration between groups. 
(F (2, 45 =5.73; p =0.006), due to a shorter CSP in the hemisphere contralateral 
to the more affected side compared with the less affected side (p=0.02) and 
healthy participants (p= 10-3). There was no difference in baseline CSP between 
the hemisphere contralateral to the less affected side and healthy participants 
(Figure 3.5). 
 
 
 
Figure 3.5 Cortical silent period duration at baseline 
 
In PD patients, the CSP is shorter in the hemisphere contralateral to the more 
affected side compared to the less affected side and also compared to healthy 
participants. (* p ≤0.05; ** p ≤0.01) 
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3.4.6 Effect of PAS on baseline corticospinal excitability 
 
There was no within-or between-subject differences in electrical stimuli counting 
errors during PAS, suggesting equivalent attention levels in different sessions. 
 
The results of the PAS effect on 1mV-MEP amplitude are illustrated in Figure 
3.6.and 3.7. Separate 2-way ANOVAs for the APB and the ADM muscles with 
factors GROUP and TIME revealed that the effect of PAS was different between 
groups in both APB (GROUP X TIME interaction (F (6, 135) =2.6; p= 0.02) and 
ADM (GROUP X TIME (F (6, 135) =3.4; p= 0.004). We explored these 
interactions further with follow-up ANOVAs in which we made separate 
comparisons between hemispheres in patients as well as comparisons of each 
hemisphere with the normal group. The less affected side had a larger response 
to PAS than the more affected side in both APB (GROUP X TIME (F (3, 90) 
=5.44; p= 10-3) and ADM (GROUP X TIME (F (3, 90) =5.55; p= 10-3) muscles. 
When the less affected side was compared to healthy participants there was no 
difference between the responses to PAS in the APB muscle; however the less 
affected side showed a spread of PAS effect to the ADM that was not present in 
healthy participants  (GROUP X TIME (F (3, 90) =4.36; p= 0.006). Finally, 
comparison of the more affected side of PD patients to healthy participants 
revealed that more affected side had less response to PAS in APB muscle. 
There was no spread of PAS response to the ADM in the more affected side or 
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in healthy participants. Within-group effects of PAS were further confirmed in 
separate ANOVAs for each group and muscle.  
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Table 3.2 Group comparisons of PAS effect in APB and ADM muscle  
   
 APB ADM 
   
Less Affected Side Vs. More Affected Side 
Vs. Healthy participants 
  
GROUP n.s. n.s. 
TIME F (3, 135) =10.1 
P<0.0001 
n.s. 
GROUP X TIME F (6,135) =2.6 
p=0.02 
F (6,135) =3.4 
p=0.004 
   
Less Affected Side Vs. More Affected side   
GROUP F (1, 30) =4.42 
p=0.04 
n.s. 
TIME F (3, 90) =6.05 
p=0.0008 
n.s. 
GROUP X TIME F (3, 90) =5.44 
p=0.001 
F (3, 90) =5.55 
p=0.001 
   
Less Affected Side Vs. Healthy Participants   
GROUP n.s. n.s. 
TIME F (3, 90) =11.1 
p=0.0001 
n.s. 
GROUP X TIME n.s. F (3, 90) =4.36 
p=0.006 
   
More Affected Side Vs. Healthy Participants   
GROUP F (1, 30)=5.17 
p=0.03 
n.s. 
TIME F (3,90) =3.39 
p=0.02 
n.s. 
GROUP X TIME F (3,90) =2.89 
p=0.04 
n.s. 
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Figure 3.6 PAS effect on corticospinal excitability, as measured by change 
in 1mV MEP amplitude in APB muscle 
 
In the APB muscle on the less affected side (blue couloured line), PAS 
increased the 1mv MEP amplitude (F (3, 45) =7.19; p<10-3; 1-way ANOVA) at 
all 3 time points : p= 0.004 at 0 min, p<10-3 at 15 min and p= 0.003 at 30 
min.There was no significant  effect of PAS in APB muscle on the more affected 
side ( red coloured line). In healthy participants ( green couloured line)  PAS 
increased 1mv-MEP amplitude in the APB muscle (F (3, 45) =4.02; p=0.01; 1-
way ANOVA) only at the 15 min time point.The data is plotted as a ratio to the 
baseline 1mV-MEP amplitude. Group differences are marked with brackets. (* 
p<0.05, ** p ≤0.01).  
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Figure 3.7 PAS effect on corticospinal excitability, as measured by change 
in 1mV MEP amplitude in ADM muscle. 
 
 
In the ADM muscle, on the less affected side PAS increased 1mv MEP 
amplitude at all 3 time points (F (3, 45) =6.23; p=10-3; 1-way ANOVA), p= 0.002 
at 0 min, p<10-3 at 15 min and p= 0.002 at 30 min .There is no significant effect 
of PAS in the ADM muscle on the more affected side or in healthy participants.   
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Correlation analysis between lateralised UPDRS score and average PAS 
response in APB disclosed that less severe motor symptoms were associated 
with a greater response to PAS (R= - 0.397; p=0.025) (Figure 3.8). There was 
no difference in our measure of attention during PAS between different TMS 
sessions or between groups.  
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Figure 3.8 Correlation between PAS induced plasticity in APB muscle and 
the clinical severity of PD 
 
The UPDRS score is associated with a larger response to PAS. Note that the 
correlation was significant even when the “outlier “indicated by the arrow (blue 
arrow: less affected side; red arrow: more affected side) is excluded from the 
analysis (R= - 0.461 p=0.01).  
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3.4.7 Effect of PAS on CSP 
 
Since the baseline CSP was different between groups, to examine the effect of 
PAS on CSP, we expressed the duration of CSP at each point after PAS as a 
ratio to the baseline CSP and computed 2-way ANOVA with factors GROUP ( 3 
levels) and TIME ( 3 levels: normalised CSP duration at 0,15 and 30 min after 
PAS). This analysis revealed a difference between groups (factor GROUP (F (2, 
45) =5.0; p= 0.01) due to an overall stronger effect of PAS on CSP duration in 
the hemisphere contralateral to the more affected side compared to healthy 
participants (p=0.01). There was no difference in the CSP duration between 
sides in PD patients or between the hemisphere contralateral to the less 
affected side in PD and healthy participants.   
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Figure 3.9 The effect of PAS on CSP duration 
 
There is a stronger effect of PAS on CSP duration in the hemisphere 
contralateral to the more affected side, comparing to healthy participants. (**p 
≤0.01) 
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3.5 Discussion 
 
The main finding of this study was that clinically asymmetric PD patients had a 
heightened response to a plasticity protocol (PAS) in the hemisphere 
contralateral to the less affected hemisphere, in contrast to an absent PAS 
response in the more affected hemisphere. The asymmetry in the 
electrophysiological findings between the hemispheres was also reflected in 
intracortical inhibition; the hemisphere contralateral to the less affected side 
showed preserved SICI and CSP, while in the hemisphere contralateral to the 
more affected side SICI was reduced and CSP shortened. These asymmetries 
cannot be explained by differences in the baseline corticospinal excitability, as 
there were no differences in IO curves and motor thresholds between the two 
sides. 
 
The absence of the PAS response in the hemisphere contralateral to the more 
affected side is in line with previous studies in patients with more advanced PD 
(Morgante et al., 2006, Ueki et al., 2006), who showed a decreased response to 
PAS in the “off” state that normalised with L-Dopa (Ueki et al., 2006). The 
reduced response to PAS is explained as being secondary to an abnormal BG 
output (Obeso et al., 2008) or to result from reduced dopamine at the cortical 
level (Gaspar et al., 1991). Since there is major bilateral (albeit asymmetric) 
dopaminergic loss even in early clinically asymmetrical PD (Tissingh et al., 
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1998) one might expect a similar reduction of PAS in both hemispheres in the 
tested patients. On the contrary, we found an increased (compared with healthy 
age matched subjects) LTP-like plasticity with loss of topographic specificity in 
the hemisphere contralateral to the less affected side suggesting that there is a 
functional reorganisation of sensorimotor cortex contralateral to milder signs of 
PD. These findings may represent a compensatory change or they may reflect 
disease related maladaptive plasticity. The negative correlation between 
severity of motor symptoms and the amount of response to PAS suggests that 
this is a compensatory change. 
 
In health, BG neurons are highly “tuned” to fire in specific circumstances related 
to different parameters of movement and to contextual cues (Mink and Thach, 
1991). There is evidence to suggest that BG dysfunction in PD leads to a loss of 
specificity of the surviving neurons and their connected structures (Bronfeld and 
Bar-Gad, 2011). Such changes could alter the precise coupling between 
sensory inputs and motor outputs that is characteristic of the sensorimotor 
cortex. Since PAS relies on the interaction between sensory afferents and 
motor output of the homologous muscle, loss of specificity could lead to spread 
of facilitation to the ADM muscle on the less affected side. The fact that the 
more affected side showed no response to PAS, even in the target APB muscle, 
might be explained by severe dopaminergic deficit in the more affected 
hemisphere, as seen in more advanced disease. Notably, it has been shown 
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that healthy subjects have an inverted “U”-shaped dopaminergic dose–plasticity 
response curve, in which low dopaminergic tone impairs plasticity, while 
moderate doses facilitate plasticity (Kuo et al., 2008, Monte-Silva et al., 2009) 
However the nature of such a non- linear relationship, although likely important 
for understanding our results, has not been specifically investigated in PD. 
 
Another novel finding of the present study is that PD patients had normal SICI in 
the less affected hemisphere. SICI was absent in the more affected 
hemisphere, in line with previous findings of reduced SICI in more advanced PD 
(Ridding et al., 1995a). We used a CS intensity of 90% of RMT to test SICI 
since this yields the clearest difference between PD and healthy individuals 
(MacKinnon et al., 2005). Detailed studies assessing the SICI- intensity curve or 
using different coil orientations indicate that GABAergic inhibitory circuits 
mediating SICI might be normal in PD while decreased SICI possibly reflects a 
decreased threshold for intracortical facilitation at higher CS intensities 
(MacKinnon et al., 2005, Hanajima et al., 2011, Ni et al., 2013). Irrespective of 
the underlying mechanism, impaired SICI in PD is thought to be related to 
dopaminergic deficiency since it is normalised with dopaminergic treatment 
(Ridding et al., 1995a, Pierantozzi et al., 2001).  Overall, our results imply that 
the dopaminergic deficit in the less affected hemisphere may still be under the 
critical threshold to trigger an impairment of SICI. This would be consistent with 
a positive correlation between disease severity and reduced SICI. 
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We found significantly shorter CSP in the hemisphere contralateral to the more 
affected side and normal CSP in the hemisphere contralateral to the less 
affected side, confirming previous reports (Cantello et al., 2007). In the present 
study, the PAS effect on CSP was not statistically different between the two 
sides in PD patients and was even stronger in the hemisphere contralateral to 
the more affected side compared to healthy participants. This is in contrast with 
advanced PD patients “off” dopaminergic treatment (Bagnato et al., 2006, 
Morgante et al., 2006) and implies that circuits mediating the PAS effect on 
CSP are preserved in early PD. 
 
A critical question which is highlighted but left unresolved by this current study 
is whether the alterations in the plasticity response in the hemisphere 
corresponding to the clinically less affected side represent a beneficial 
compensatory change that helps prevent motor symptoms progressing or a 
maladaptive change that reflects disease progression. It might be possible to 
determine with follow-up of early asymmetric patients if persistence of 
enhanced plasticity is associated with slower progression of the motor signs on 
the less affected side, suggesting that this electrophysiological change reflects 
a beneficial compensatory process, or the converse which would suggest that it 
reflects a maladaptive process. The change in asymmetry of the PAS response 
between hemispheres over time could be developed into a electrophysiological 
marker of disease progression.   
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 Changes in sensorimotor cortical Chapter 4
plasticity and intracortical inhibition with 
progression of Parkinson’s disease: 
revealing compensatory mechanisms 
 
Having demonstrated interhemispheric difference in sensorimotor cortical 
plasticity in asymmetric PD patients, the following set of experiments sough to 
answer the critical question of whether or not increased sensorimotor cortical 
plasticity in the hemisphere contralateral to the less affected side reflects an 
adaptive, compensatory change that helps prevent motor symptoms emerging 
or it represents a maladaptive change that heralds the symptom progression. 
We therefore investigated the relationship between the change in PAS 
response and the other TMS measures and progression of motor signs, by 
following up the same patients for a period of 1 year. 
 
The work presented in this Chapter is submitted in Journal of Neurology, 
Neurosurgery and Psychiatry: Kojovic M,  Kassavetis P, Bologna M, Pareés I, 
Rubio-Agusti I, Beraredelli A, Edwards MJ, Rothwell JC an  Bhatia KP. 
Longitudinal electrophysiological study in Parkinson’s disease: revealing 
compensatory changes 
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4.1. Summary 
 
The same patients who underwent the experiments presented in Chapter 3 
were clinically examined and retested with TMS after 6 and 12 months. On each 
occasion we measured MTs, IO curves, SICI, ICF and CSP and sensorimotor 
cortical plasticity using the excitatory PAS protocol. Patients were also rated on 
the UPDRS scale. We found no difference and no further change in MTs 
between sides. The IO curve was steeper (with higher intensities) in the 
hemisphere contralateral to the more affected side and this interhemispheric 
difference remained constant. The asymmetry in SICI also persisted at 1 year. 
In contrast, the initially reduced CSP in the hemisphere contralateral to the 
more affected side subsequently increased, resulting in a side-to-side 
equalisation of CSP. The interhemispheric differences in sensorimotor cortical 
plasticity were still present after 1 year. In individual patients, the decline in 
asymmetry of the CSP and the PAS response was correlated with the reduction 
in asymmetry of the clinical symptoms. We suggest that an initially reduced 
CSP in the hemisphere contralateral to the more affected side and increased 
plasticity in the hemisphere contralateral to the less affected side may be 
compensatory, preventing clinical expression of disease progression. 
4.2. Introduction 
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In PD motor symptoms emerge after a prolonged period of dompaminergic loss, 
suggesting there is activity of adaptive or compensatory mechanisms (Zigmond 
et al., 1990, Hornykiewicz, 1998, Lee et al., 2000, Appel-Cresswell et al., 2010). 
In the early preclinical stage, adaptive changes occur within the nigrostriatal 
synapses, and through various mechanisms to keep synaptic dopamine at 
relatively constant level (Hornykiewicz and Kish, 1987, Zigmond et al., 1989, 
Zigmond, 1997). With further neurodegeneration, nigrostriatal compensatory 
mechanisms can no longer keep up with on-going dopaminergic cell loss and 
BG output structures become further involved in the compensatory process 
(Bezard et al., 2003, Boulet et al., 2008). Finally, by the time of the emergence 
of motor signs, compensation presumably engages cerebral circuits outside the 
BG (Bezard et al., 2001, Obeso et al., 2004) including thalamo-cortical 
connections and the cerebellum (Bezard et al., 2003, van Nuenen et al., 2009, 
van Nuenen et al., 2012). The role of the sensorimotor cortex in compensation 
for the dopaminergic deficit has been less well studied (Sabatini et al., 2000). 
As found in our previous study, presented in Chapter 3, clinical asymmetry of 
motor signs in early PD is reflected in interhemispheric asymmetry of the 
electrophysiological measures: the less affected (LA) hemisphere has increased 
sensorimotor cortical plasticity as measured by the response to PAS25 protocol, 
while in the more affected (MA) hemisphere plasticity is reduced. A critical 
question arising from these results is the pathophysiological significance of 
enhanced plasticity: does increased motor cortical plasticity on the LA 
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hemisphere reflect an adaptive change that helps prevent motor symptoms 
emerging or does it represent maladaptive change that heralds disease 
progression? In the present study we aimed to answer this question by 
investigating the relationship between change in the PAS response (and other 
TMS measures) and progression of the motor signs in the same PD patients 
during a period of one year. 
 
4.3. Methods 
 
4.3.1. Patients 
 
From the 16 drug- naive patients who completed baseline set of experiments 
described in Chapter 3, 12 patients completed the follow-up study. The 
remaining four patients were unavailable due to different reasons: one was 
undergoing treatment for newly diagnosed breast carcinoma, one lived remotely 
and was not keen to travel the long distance and two decided not to participate 
further, without giving particular reasons. Subsequent to the baseline set of 
experiments (for which all patients were drug-naïve), the patients underwent a 
consultation with a movement disorders specialist and were given all the 
necessary information about available symptomatic treatments. Because of the 
ethical issues, patients were not randomised into treated and untreated groups, 
but it was dependent upon themselves and their treating physician to decide 
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whether and when to start treatment for PD and with what kind of dopaminergic 
medications. Irrespective of the on-going treatment, patients were retested at 6 
months and 12 months. At the time of follow up, all treated patients had been on 
a stable dosage of dopaminergic medication for previous the 3 months and 
were tested in an off-state after overnight withdrawal of treatment (at least 12 
hours). Patients’ demographic, clinical and treatment data are given in table 4.
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Table 4.1 Demographic and clinical characteristics of the patients and treatment data
Patient 1 2 3 4 5 6 7 8 9 10 11 12 Mean 
(SEM) 
Age 34 44 66 62 48 62 52 71 67 64 50 61 56.7 
(3.2) 
Sex F M M F M M M M M M M M  
Treatment 
baseline 
/ / / / / / / / / / / /  
Treatment 
6 months 
ras 
1mg 
rop 
8mg 
ras 
1mg 
 
ras 
1mg 
 
prp 
1.5mg 
L-
Dopa 
300 
mg 
/ / / / / / /  
Treatment 
12 
months 
ras 
1mg 
rop 
8mg 
ras 
1mg 
 
ras 
1mg 
 
prp 
1.5mg 
L-
Dopa 
300 
mg 
ras 
1mg 
prp 
1.5mg 
 
ras 1mg 
prp ER 
0.375 
mg 
ras 1mg 
L-Dopa 
300 mg 
L-Dopa 
300 mg 
rotg 
6mg 
/ /  
UPDRS 
LA 
baseline 
1 2 1 0 1 0 1 1 1 2 7 2 1.58 
(0.42) 
UPDRS 
LA 6 m 
1 0 3 1 1 1 2 1 2 4 11 4 2.58 
(0.53) 
UPDRS 
LA 12 m 
2 1 2 2 1 4 3 5 2 3 9 6 3.33 
(0.37) 
  
 
8
8
 
 
Abbreviations: F, female; M, male ras,rasegiline; rop,ropinirol; prp, pramipexole; prp ER, pramipexole extended release; UPDRS LA, UPDRS on the 
less affected side; UPDRS MA, UPDRS on the more affected side;  UPDRS total, total motor UPDRS
UPDRS 
MA 
baseline 
18 8 5 12 11 9 6 10 4 14 18 3 9.83 
(0.46) 
UPDRS 
MA 6 m 
 
13 11 8 10 13 10 7 10 4 17 15 5 10.25 
(0.35) 
UPDRS 
MA 12 m 
 
21 8 7 13 18 8 8 10 4 15 15 9 11.33 
(0.43) 
UPDRS 
index 
baseline 
0.89 0.60 0.67 1 0.83 1.00 0.71 0.82 
 
0.60 0.75 0.44 0.2 0.71 
(0.08) 
UPDRS 
index 6 m 
0.86 1.00 0.45 0.82 0.86 0.82 0.56 0.82 0.33 0.62 0.15 0.11 0.62 
(0.11) 
UPDRS 
index 12 
m 
0.83 0.78 0.56 0.73 0.89 0.33 0.45 0.33 0.33 0.67 0.25 0.20 0.53 
(0.1) 
UPDRS 
total 
baseline 
24 12 9 12 18 10 8 18 9 26 33 5 15.33 
(0.63) 
UPDRS 
total 
6months 
17 14 17 13 20 12 9 24 10 34 31 9 17.5 
(0.85) 
UPDRS 
total 12 m 
26 12 14 16 24 18 17 20 10 28 38 22 20.42 
(0.5) 
Cont. 
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4.3.2. Clinical measures 
 
Clinical disease severity was assessed with the motor section of the MDS-
UPDRS scale (Goetz et al., 2008b). For the less and more affected side, 
lateralised UPDRS scores were calculated as the sum of the items for 
bradykinesia, rigidity and tremor (items 3.3 to 3.8 and 3.15 to 3.17) for each 
side. To express the severity of motor symptoms and their distribution between 
sides within one measure we calculated an UPDRS asymmetry index, given as: 
(MA-LA)/ (MA + LA), where MA and LA represent lateralised UPDRS score from 
more and less affected side respectively (Espay et al., 2005, Li et al., 2007). 
The UPDRS asymmetry index ranges from 1 when symptoms are only on one 
side (i.e. complete asymmetry of symptoms) to 0, when symptoms are evenly 
distributed. 
 
4.3.3. EMG recordings and TMS 
 
We used exactly the same methods as performed for the baseline set of 
experiments (chapter 3). 
 
4.3.4. Experimental design 
 
At baseline, 6 months and 12 months patients were tested on both 
hemispheres, corresponding to the less and more affected side in different TMS 
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sessions, separated by 1 week (Figure 4.1). Patients were always studied at 
the same time of the day, during morning hours. The motor assessment with the 
UPDRS scale was performed before the TMS testing. The order of the tested 
hemisphere was balanced between subjects.  In each session we first 
measured RMT, AMT, 1mV MEP, IO curve, SICI, ICF and CSP. Motor cortex 
plasticity was probed using PAS25. We assessed the effect of PAS25 on 1mV 
MEPs amplitude at 3 time points after PAS: 0, 15 min and 30 min. 
 
 
 
Figure 4.1 Follow up study design  
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4.3.5 Statistical analysis 
 
Since all patients were tested “off” dopaminergic medications, we began our 
analysis by considering treated and untreated patients together. Friedman 
ANOVAs were used to assess changes in the motor total UPDRS score, the 
lateralised UPDRS score and the UPDRS index over time (baseline, 6 months, 
and 12 months). To test the changes in electrophysiological measures we used 
ANOVAs with factors TIME and SIDE (for RMT, AMT, CSP and ICF) or 
ANOVAs with additional within-subjects factors depending on the variable 
tested. For changes of IO curves factor STIMULUS INTENSITY (10 levels of 
stimulator output intensity) was used. For analysis of SICI, for each ISI, 
conditioned MEP amplitude was averaged and normalized to average 
unconditioned MEP amplitude and entered into ANOVA with factors: SIDE, 
TIME and ISI ( 2,3, and 4 ms). For analysis of the PAS effect, for each time 
point after PAS the amplitude of the MEP was averaged and normalized to the 
average MEP amplitude before PAS  and entered into ANOVA with factors: 
TIME, SIDE, MUSCLE (APB  and ADM) and TIME POINT AFTER PAS (0 , 15 
min and 30 min after PAS ). In addition, we expressed the interhemispheric 
difference in electrophysiological measures between the LA and MA side as the 
ratio between sides and entered it in ANOVA with factor TIME. 
 
In a secondary analysis, we compared treated and non-treated PD patients. At 
6 months, we used ANOVA with the factor GROUP (treated vs. untreated) as a 
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between-subject factor and factor TIME (baseline vs. 6 months) and SIDE as 
within subjects factor. At 12 months, the majority of patients were treated and 
the difference between treated and untreated could not be assessed due to the 
small number of untreated patients.  We however assessed if there were 
differences between “early” vs. “late” treated patients. Early treatment refers to 
initiation of treatment within 1 month of the baseline set of experiments (5 
patients), while late treatment refers to initiation of treatment after the second 
set of experiments (5 patients) or no treatment at all at the time of 3rd set of 
experiments (2 patients). 
 
To determine the relationship between changes in motor scores and the 
electrophysiological measures over the all three longitudinal time points we 
computed within-subject correlation coefficients (Bland and Altman, 1995) using 
the UPDRS index as an outcome variable, while subjects  and the 
interhemispheric ratio of the electrophysiological measure of interest ( PAS 
ratio, SICI ratio or CSP ratio)  were predictor variables.  Statistical analysis was 
done on the raw data. However, to plot the correlation figures, data  at each 
time point were first  expressed as a difference ( delta) between measurement  
at that time point and patient‘s average of all 3 time points  and this value was 
then expressed as a fraction of the individual patient's average, using the 
following computation : (CSP ratio baseline, 6 or 12 months- average CSP ratio) / 
average CSP ratio or (PAS ratio baseline, 6 or 12 months- average PAS ratio) / average 
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PAS ratio; and (UPDRS index baseline, 6 or 12 months- average UPDRS index) / 
average UPDRS index. 
4.4. Results 
 
4.4.1. Clinical measures 
 
Results on changes in clinical measures are illustrated in Figure 4.2. As noted 
in the table 4. 1, none of the patients were taking any anti-parkinsonian 
medication at baseline, five had started treatment at 6 months and 10 of the 12 
were treated at 12 months. As expected, the patients’ practically defined “off” 
state deteriorated gradually over time. A Friedman ANOVA on total UPDRS 
score revealed a significant effect of TIME (χ2  =12.6; p =0.002) which was due 
to the score being higher at 12 months compared to baseline (p=0.003), while 
the difference between baseline vs. 6 months and 6 vs. 12 months just failed to 
reach significance (p=0.06 and p=0.09, respectively).  Breaking down the data 
into results from the LA and MA sides showed that although the scores 
increased on both sides, this was significant only on the LA side (χ 2 =10.6; p 
=0.005), due to the score being higher at 12 months compared to baseline 
(p=0.007), while there was no significant difference between 6 months and 
baseline (p=0.06) or 6 vs. 12 months (p=0. 2). For MA side, there was no 
significant change in the UPDRS score over time (χ 2 =3.3; p =0.2). Despite 
changes in the lateralised scores, the side difference in symptom severity 
persisted, with the MA side having higher UPDRS at all 3 time points (Wilcoxon 
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sign rank test: p = 0.002 at baseline, p = 0.002 at 6 months and p = 0.002 at 12 
months). 
Overall, the UPDRS asymmetry index fell over the 12 month period (χ 2 =3.3; p 
=0.01). It was smaller at 12 months compared to baseline (p=0.03), while there 
was no difference between baseline and 6 months or 6 and 12 months (p=0.06 
and p=0.4, respectively). 
 
 
 
Figure 4.2 Change in clinical measures 
 
(A) total motor UPDRS score , (B) UPDRS asymmetry index and (C) lateralised 
UPDRS score over 12 months period. (**p<0.01).  
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4.4.2. Baseline corticospinal excitability 
 
For RMT and AMT, ANOVA revealed no significant effect of the factors SIDE or 
TIME and no significant SIDE x TIME interactions, indicating there were no 
differences in motor thresholds between sides and no change over time. For IO 
curves, a 3-way ANOVA revealed significant effect of SIDE (F (1, 11) =6.08; p 
=0.04) and SI (F (9, 99) =52.7; p <10-3), and significant SIDE X SI interaction (F 
(9, 99) =2.65; p=0.008). This was due to higher MEPs on the MA side with SI: 
150%, 160% and 170% RMT (p= 0.04, p=0.03 and p=10-3, respectively). The 
factor TIME was not significant. These results indicate that the IO curve was 
steeper on the MA hemisphere at all 3 assessments (Figure 4.3).  
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Figure 4.3 IO Curve- change over 12 months 
 
The mean MEP amplitude (±SEM) is given on the y-axis against the stimulus 
intensity given on the x-axis (as a percentage of RMT stimulus intensity). There 
is an interhemispheric difference in IO curve: at higher stimulus intensity IO 
curve is steeper in the hemisphere contralateral to the more affected side 
comparing to the hemisphere contralateral to the less affected side. This 
difference between sides is evident at baseline, and even more so at 6 months 
and 12 months.  
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4.4.3. SICI 
 
Like the IO curves above, SICI was less effective in the MA hemisphere but did 
not change over the 12 month assessment period. A 3-way ANOVA showed 
significant effects of SIDE (F (1, 11) =11.1; p=0.006) and ISI (F (2, 22) =10.51; 
p <10-3) due to the fact that there was less effective SICI on the MA hemisphere 
and greater SICI at ISIs 2 ms and 3 ms compared to 4 ms (p <10-3 and p= 0.01, 
respectively). There was no effect of TIME nor any 2-way or 3-way interactions 
(Figure 4.4). There was no correlation between changes in SICI 
interhemispheric ratio and changes in UPRDS asymmetry index. 
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Figure 4.4 Short Interval Intracortical Inhibition—change over 12 months 
 
There is an interhemispheric difference in SICI, evident at baseline, at 6 months 
and at 12 months. 
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4.4.4. ICF 
There was no significant effect of factors SIDE and TIME and no significant 
SIDE x TIME interaction, indicating no differences in ICF between sides and no 
change over time (Figure 4.5). 
 
 
 
Figure 4.5 Intracortical Facilitation— change over 12 months 
 
There is no significant interhemispheric difference in ICF (ISI 15 ms) and no 
significant change over time. Data is plotted as a ratio to the unconditioned 
MEP amplitude. 
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4.4.5. CSP 
 
ANOVA revealed no significant effect of the factors TIME or SIDE. However 
there was significant TIME X SIDE interaction (F (2, 22) =5.42; p=0.01) due to 
the fact that the CSP in the MA hemisphere was longer at 6 and 12 months 
compared to baseline (p=0.02 and p= 0.02, respectively). Thus, an initially 
shorter CSP in the MA hemisphere increased at 6 months, resulting in 
equalisation of the CSP between sides (Figure 4.6). There was no change on 
the LA hemisphere. Within-subject correlation analysis revealed that the 
reduced difference between the CSP duration in the two hemispheres was 
correlated with the decrease in UPDRS asymmetry index (r=0.5, p=0.02) 
(Figure 4.7) 
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Figure 4.6 Cortical silent period— change over 12 months 
 
CSP duration: At baseline, CSP is shorter in the more affected hemisphere 
compared to the less affected hemisphere. After 6 months CSP increased in the 
more affected hemisphere , while there was no significant change in CSP 
duration in the less affected hemisphere ,  resulting in equalisation in CSP 
between sides  at 6 and 12 months(**p<0.01)  
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Figure 4.7 Within-subjects correlation between change in UPDRS 
asymmetry index and change in CSP interhemispheric ratio 
 
This correlation shows that a decrease in CSP interhemispheric ratio is 
associated with decrease in UPDRS asymmetry index, thus with progression of 
motor signs.  The black line indicates the overall correlation for the whole group. 
Different colours correspond to different patients and each patient is 
represented with 3 points (for baseline, 6 and 12 months measurements). 
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4.4.6 PAS 
 
There was no within-or between-subject difference in electrical stimuli counting 
errors during PAS, thus excluding differences in attention levels in different 
sessions. 
 
For PAS response, ANOVA revealed significant effect of the factor SIDE (F (1, 
11) =34.0; p<10-3) due to the larger response on the LA hemisphere. Factors 
TIME, MUSCLE and TIME POINT AFTER PAS and all interactions between 
main factors were not significant. These results indicate that the asymmetry of 
the PAS response between sides detected at baseline was still present at 6 and 
12 months (Figure 4.8).  
 104 
 
 
 
Figure 4.8 Change of PAS response 
 
The interhemispheric difference in PAS response (expressed as an averaged 
PAS response for 0, 15 and 30 min after PAS) is evident at baseline, at 6 
months and at 12 months, in both APB and ADM muscle. 
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However there were substantial inter-individual differences in how PAS 
changed over time. Within individual patients, a decrease in the PAS 
interhemispheric ratio was associated with decrease in UPDRS asymmetry 
index (Figure 4.9).There was a positive within-subjects correlation between 
APB interhemispheric (and ADM interhemispheric ratio) and UPDRS 
asymmetry index (APB: r=0.51, p=0.03 and ADM: r=0.43, p=0.03). 
 
 
 
Figure 4.9 Within-subjects correlation between change in UPDRS 
asymmetry index and change in PAS interhemispheric ratio. 
 
This correlation shows that the decrease in PAS interhemispheric ratio in both 
APB and ADM muscles is associated with a decrease in the UPDRS asymmetry 
index, and thus with progression of the motor signs.  Black lines indicate the 
overall correlation for the whole group.  
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4.4.7 Treated vs. untreated patients and Early vs. Late treated patients 
 
For all clinical measures and all TMS measures there was no difference 
between treated and untreated patients or between early and late treated, as 
indicated by no significant effect of the factor GROUP and no interactions of 
GROUP with TIME in any of the analysis. 
 
4.5. Discussion 
 
This is the first longitudinal study that was design to address changes in 
different electrophysiological measures with the progression of early PD. In the 
first year after initial presentation, there was a gradual decrease in clinical 
asymmetry. Despite the clinical deterioration, there was no overall change in: 
motor thresholds to TMS, IO curves of MEP recruitment; GABAa inhibition 
measured in the SICI protocol, ICF; or synaptic plasticity of sensorimotor cortex 
measured using the PAS protocol. Initial asymmetries in IO curves, SICI and 
PAS persisted between the less and more affected hemispheres. The only 
physiological measure that changed was the GABAb mediated CSP, which was 
shorter in the LA hemisphere at onset but became equalised between the two 
sides after 6 months and remained the same after 1 year. Although the sample 
was small, there was no difference between “early” and “late” treated patients, 
similar to previous physiological work that suggested that there are no long-term 
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modifying effects of L-Dopa on electrophysiological measures (Kacar et al., 
2012). 
The apparent lack of change in the mean data, however, conceals a variation in 
the rate of progression in individual patients. When we expressed the clinical 
scores conventionally as an asymmetry index, which normalises the between-
side differences to the total score on both sides, there was a significant 
correlation between the reduction in clinical asymmetry and the corresponding 
reductions in the asymmetry of CSP and PAS response. 
 
Changes in intracortical inhibition and facilitation 
 
Pharmacologically, short-interval intracortical inhibition is primarily mediated by 
GABAa receptors and the cortical silent period is subserved by GABAb 
receptors (Ziemann, 2004, Di Lazzaro et al., 2006). Our results on SICI and 
CSP suggest that these circuits are differently affected during the course of PD. 
While the interhemispheric difference in SICI detected at baseline persisted 
after 6 and 12 months, the initial asymmetry of the CSP between hemispheres 
subsequently disappeared: the shorter CSP on the MA side increased towards 
values for the LA side at 6 months. Interestingly, a decrease in the 
interhemispheric CSP ratio correlated with a decrease in the UPDRS 
asymmetry index. Thus an initially shorter CSP in the MA hemisphere may 
reflect a compensatory change serving to facilitate the movement on the side 
most affected by symptoms. Prolongation of CSP could also be interpreted as 
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an effect of dopaminergic treatment, but this seems unlikely given that the same 
change occurred in both treated and untreated patients. 
There was no side difference in ICF and no change over 1 year. Many previous 
studies (Ridding et al., 1995a, Berardelli et al., 1996, Strafella et al., 2000, 
Kacar et al., 2012) showed normal ICF in patients with more advanced PD, 
which together with our results suggest that there is no major involvement of the 
interneurons mediating ICF during the course of PD. 
 
Changes in sensorimotor cortical plasticity 
 
We described in Chapter 3 that early PD patients have an enhanced response 
to PAS25 on the LA side while the response to PAS25 is absent on the MA 
side. In the present study, we demonstrate that the interhemispheric difference 
in sensorimotor cortical plasticity still persists after 1 year. However, this 
conceals a large variability between patients. In some patients, the asymmetry 
in PAS response between hemispheres declined whereas there was little 
change in others. Overall, the rate of change in PAS asymmetry correlated well 
with the change in asymmetry of the UPDRS: the greater the reduction in PAS 
asymmetry, the greater the reduction in the asymmetry of the UPDRS. Notably, 
asymmetry in IO curves is unlikely to be the cause of an asymmetric PAS 
response in our patients, because if this were the case, we would expect a 
greater response to PAS on the side with the steeper IO curve, i.e. the MA side 
(Rosenkranz, 2010).  We found the opposite pattern. 
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Therefore our results challenge the classical view of a generally reduced   
sensorimotor cortical plasticity in PD. Apart from one study (Bagnato et al., 
2006), there is a general consensus that the response to PAS25 is reduced or 
absent in patients tested “off” medications (Morgante et al., 2006, Ueki et al., 
2006, Kacar et al., 2012, Kawashima et al., 2013, Kishore et al., 2013, Udupa 
and Chen, 2013). However, all these studies dealt with patients who had more 
advanced PD compared to our patients. Our present results show that motor 
cortex plasticity can change from being increased early in the course of disease 
(as it was in the LA hemisphere of our patients), to a complete loss of plasticity 
response (as in the MA hemisphere in the present patients). We suspect that 
the two sides in our patients will reach a similar pattern of electrophysiological 
abnormalities with further disease progression. 
 
Our hypothesis is that the interhemispheric difference in sensorimotor cortical 
plasticity in early PD represents an adaptive rather than maladaptive change. 
The increased plasticity at, and perhaps prior to clinical onset may allow cortical 
areas to compensate in some way for the underlying deterioration in BG output. 
A possible role of interhemispheric interaction  in compensation for 
dopaminergic deficit  has been proposed by Blesa et al.(Blesa et al., 2011), 
based on the 18F-DOPA PET study of asymmetric PD patients and 
experiments on MPTP lesioned monkeys. It was proposed that a higher 
asymmetry of nigrostriatal dopamine deficit, as defined by the relatively 
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preserved dopaminergic innervation in the less-affected compared to the more 
affected striatum, might relate to a better compensatory capacity, resulting in 
higher thresholds for the appearance of motor symptoms on the clinically less 
affected side. Our study also supports the role of asymmetric hemispheric 
reorganisation in compensation for PD, although it cannot address the 
mechanism through which this might be occurring. 
 
Limitations of the study 
 
There are some interpretational issues I would like to mention. The association 
between change in interhemispheric difference in cortical plasticity and clinical 
progression is not necessarily sufﬁcient to confirm a direct relationship. Thus, 
we cannot exclude the existence of some third factor that could have influenced 
both variables independently. This however seems less likely in the light of a 
number of previous studies showing the relationship between various excitatory 
plasticity protocols that work by inducing LTP-like changes at cortical synapses, 
and improvement in the motor symptoms of PD (Khedr et al., 2003, Khedr et al., 
2006, Lomarev et al., 2006). 
 
We found no significant difference between treated and untreated patients or 
between early and late treated patients in clinical or electrophysiological 
measures, suggesting that early initiation of dopaminergic treatment does not 
affect the electrophysiological changes that occur with disease progression. 
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However, there are limitations to be considered. First, the present study was not 
primarily aimed to assess the effect of treatment, considering the small number 
of patients in each group and the relatively short follow-up period. Therefore, 
subtle differences could have been missed and we cannot exclude that a 
potentially modifying effect of early dopamine replacement would become 
apparent after a longer follow- up period.  However, this is not the first time that 
no differences between treated and non-treated patients have been identified.  
Kacar et al. (2012) also found no clinical differences and no differences in TMS 
measures, including PAS response, between PD patients who have never been 
treated with dopaminergic medications and the group of treated patients with 
similar disease duration, arguing against a disease modifying effect of early 
treatment. 
Finally, as we used as measures of clinical progression a change in lateralised 
UPDRS score and UPDRS index, that both take into account 3 cardinal motor 
signs (i.e. rigidity, bradykinesia and tremor) together, we cannot comment if 
predominant presence of one of the motor signs is associated with specific 
electrophysiological changes in the sensorimotor cortex. This could be 
addressed in future studies with a large enough sample of PD patients. 
 
Conclusion 
Changes in motor cortex plasticity and GABAb intracortical inhibition are likely 
sensitive electrophysiological measures of clinical progression in PD. Enhanced 
cortical plasticity and shortening of the CSP probably reflect compensatory 
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processes in early PD, which might be relevant for potential therapeutic 
interventions using non-invasive brain stimulation techniques.   
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 Modulation of sensorimotor Chapter 5
cortical plasticity with Botulinum Toxin 
injections in primary dystonia 
 
Abnormal brain plasticity is thought to play a major role in pathophysiology of 
primary dystonias. In particular, it has been shown that sensorimotor cortical 
plasticity is increased as measured by response to a PAS protocol that relies on 
the integration of sensory input and motor output.  In the following set of 
experiments, we investigated if modification of the afferent input by botulinum 
toxin (BT) injections may affect sensorimotor cortical plasticity. 
 
The work presented in this Chapter is published in the form of a research 
article: Kojovic M, Caronni A, Bologna M, Rothwell JC, Bhatia KP, Edwards MJ. 
Botulinum toxin injections reduce associative plasticity in patients with primary 
dystonia. Mov Disord. 2011 Jun;26(7):1282-9. 
 
5.1 Summary 
BT injections ameliorate dystonic symptoms by blocking the neuro-muscular 
junction and weakening dystonic contractions. We investigated whether BT 
injections in dystonia patients also affect the integrity of sensorimotor cortical 
plasticity, one of the key pathophysiological features of dystonia. We applied 
 114 
 
rPAS protocol, known to induce LTP-like changes in the primary motor cortex 
hand area (Quartarone et al., 2006a) to 12 patients with cervical dystonia 
before, 1 and 3 months after BT injections to the neck muscles. M1 excitability 
was probed by measuring TMS-evoked MEPs before and after rPAS. We also 
measured IO curve, SICI, ICF, short afferent inhibition (SAI) and long afferent 
inhibition (LAI) in the hand muscles and the clinical severity of the dystonia. We 
found that before BT, rPAS significantly facilitated MEPs in hand muscles. 1 
month after injections this effect was abolished, with partial recovery after 3 
months. There were significant positive correlations between the facilitation 
produced by rPAS and (i) the time elapsed since injections of BT and (ii) the 
clinical dystonia score. One effect of BT treatment is to modulate the afferent 
input from the neck and we propose that the subsequent reorganisation of the 
motor cortex representation of the hand muscles may explain the effect of BT 
on motor cortex plasticity. 
 
5.2 Introduction 
 
The lack of inhibition at multiple CNS levels (Berardelli et al., 1985, Nakashima 
et al., 1989, Ridding et al., 1995b) and abnormal cortical plasticity contribute to 
the pathophysiology of dystonia (Quartarone et al., 2003, Edwards et al., 2006). 
In dystonia, enhanced sensorimotor cortical plasticity extends beyond the 
clinically affected region and may be detected in the unaffected upper limbs of 
patients with cervical dystonia (Quartarone et al., 2008). BT inhibits 
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acetylcholine release from α -motoneurons and is used as an effective 
treatment for different forms of focal and segmental dystonia. Although the 
clinical improvement roughly parallels weakness, it is commonly observed that 
the clinical benefit seems out of proportion to the weakness caused by the 
injections, suggesting an additional, possibly central effect of BT (Priori et al., 
1995, Trompetto et al., 2006). The effects of BT in dystonia have been 
addressed in several studies. (Priori et al., 1995, Byrnes et al., 1998, Gilio et al., 
2000, Thickbroom et al., 2003, Quartarone et al., 2006b, Trompetto et al., 
2006). For example, the tonic vibration reflex in patients with writer’s cramp is 
suppressed to a greater extent than maximal voluntary contraction (MVC) and 
maximum M wave amplitude (M-max) after BT injections and this effect persists 
even when  MVC and M-max returned to baseline, even though some patients 
still experienced some benefit from the injections (Trompetto et al., 2006). BT 
treatment normalizes reduced spinal reciprocal inhibition (Priori et al., 1995) and 
reduced intracortical inhibition (Gilio et al., 2000). Abnormal cortical hand 
representations revert to normal in patients with focal limb or cervical dystonia 
after BT injections (Byrnes et al., 1998, Thickbroom et al., 2003). BT has also 
been shown to reduce the abnormally enhanced plasticity of the trigeminal blink 
reflex in patients with blepharospasm (Quartarone et al., 2006b). These effects 
have all been explained in part by a change in the Ia afferent input from muscle 
spindles caused by BT (Filippi et al., 1993, Rosales et al., 1996). 
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In the present study, we hypothesized that BT injections may change the 
response to an experimental cortical plasticity protocol, which is known to be 
enhanced in primary dystonia (Edwards et al., 2006, Weise et al., 2006). We 
studied the response to PAS in patients with cervical dystonia (CD) (with or 
without arm involvement) before, 1 month and 3 months after BT injections into 
the neck muscles. 
 
5.3 Methods 
5.3.1 Participants 
We studied 12 patients (8 women, mean age: 53 years; range: 30-72 years) 
with clinically definite primary CD. Six patients had pure focal CD and 6 patients 
had CD with mild arm involvement (4 writing dystonia and 2 dystonic arm 
tremor) that did not require treatment. For the clinical assessment of dystonia 
we used the Burke-Fahn-Marsden (BFM) scale in order to capture the additional 
arm involvement in CD and any possible change with BT injections to the neck 
muscles. The mean duration of the disease was 14 years (range: 3-30 years) 
and all but one patient was chronically treated with BT type A (Dysport, Ipsen, 
UK), for an average of 7 years (range: 1-21 years). BT was injected solely into 
the cervical muscles with a dose ranging from 325 to 850 IU (mean dose 487 
IU). None of the patients had ever had injections into their arm muscles.  At the 
time of the study, no patient was receiving medication that we believe could 
affect the measures performed.  Clinical and demographic data are given in 
Table 5.1. All patients were the right-handed.  
  
 
1
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Table 5.1 Clinical features of patients with primary dystonia 
          
Patients Age 
(yrs) 
 
Disease 
Duration 
(yrs) 
BT therapy 
Duration 
(yrs) 
BT 
lasinjection 
total dose 
(IU) 
BFM 
Before 
BT 
BFM 
1 m-onth after 
BT 
BFM 
3 months after  
BT 
Time from Muscles injected 
3 months after  
BT 
  d r ti (yrs) d r ti (yrs) (IU) pre BT month months last 
BT(wks) 
injected 
         
1* 
56 7 3 480 4 4 6 13 
spl;trp 
2 
72 13 10 500 8 1 0.5 12 
spl;scm;ls 
3 
52 5 3 425 4 2 4 18 
spl;scm;ls 
4* 
42 28 8 500 4 2 2 16 
spl.scm.tr 
5 
30 3 1 325 4 2 4 16 
spl;scm 
6* 
65 30 21 850 4 0 2 18 
spl;scm 
7 
37 8 6 425 4 2 2 15 
spl;scm;tr;ls 
8* 
61 26 0 440 2 2 2 / 
spl 
9 
55 21 20 500 6 4 4 37 
spl;scm;ls 
10* 
51 14 2 350 2 2 4 21 
spl;scm 
11 
61 13 9 450 4 2 4 23 
spl 
12* 
58 3 2 600 6 4 6 16 
spl;scm;ls;tr 
Mean 53 14 7 487 4.3 2.2 3.4 
17 
 
Abbreviations: yrs, years; wks, weeks; IU, international units; BFM, Burke-Fahn-Marsden scale; spl, splenius; scm, sternocleidomastoid; ls, levator 
scapulae; tr, trapezius. Asterisks (*) indicate patients affected by cervical dystonia with arm involvement: patients 1and 6- dystonic tremor: patients 
4, 8, 10, 11- writing dystonia. 
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5.3.2 EMG recordings and TMS 
 
EMG recordings were made from the APB and FDI muscles. Single and paired 
pulse TMS of the left primary motor cortex was applied as indicated in Chapter 
2. The IO curve was assessed using SI from 70 to 130 % RMT. The SICI and 
ICF were probed at ISI of 2 and 12 ms, respectively. 
 
Short-latency afferent inhibition (SAI) and long-latency afferent inhibition (LAI) 
were assessed according to the protocol by Tokimura et al.(2000).For the 
electrical median nerve stimulation, the intensity was set just above the 
threshold for evoking a visible twitch of the thenar muscles (approximately three 
times perceptual threshold). The intensity of the TMS was set to evoke 1mV-
MEPs. SAI was probed at the ISI of 25 ms. At this ISI, in healthy subjects, SAI 
is present and may be modified by rPAS (Quartarone et al., 2006a). LAI was 
probed at ISIs of 200 ms. For both SAI and LAI, the electrical stimulus preceded 
the TMS stimulus. 
 
rPAS protocol was delivered using Magstim Rapid² stimulator (Magstim 
Company, Carmarthenshire, Wales, UK), as described by Quartarone et al. 
(2006a).The protocol consisted of 600 pairs of median nerve and TMS stimuli 
continuously delivered on the APB hot spot of the left hemisphere, at a rate of 5 
Hz. Each TMS stimulus was preceded by an electrical conditioning stimulus 
given to the right median nerve at ISI of 25 ms. The median nerve was 
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stimulated at the wrist using standard bar electrodes with the cathode 
positioned proximally. The median nerve electrical stimulation was performed 
with constant current square wave pulses with a pulse width of 500µs. The 
intensity for the median nerve stimulation was 200% of the perceptual 
threshold. The intensity of TMS was individually adjusted to 90% of the AMT. 
 
5.3.3 Experimental design 
 
All subjects were studied in three sessions: before BT injections, 1 month after 
3 months after BT injections (Figure 5.1). In all subjects, at least 3 months 
elapsed between the previous injections and the first experimental session 
(Table 5.1). Before each session, patients underwent a clinical assessment with 
the BFM scale. 
 
In each session the TMS parameters (RMT, 1mV-MEP amplitude, SICI, ICF, 
SAI and LAI) were measured at four time points: before rPAS, immediately after 
rPAS (0 min, 30 minutes and 60 minutes after rPAS. Before rPAS in each of 
three experimental sessions, we also measured the IO curve in 7 steps, using 
the TMS intensity from 70 to 130% of the 1mV-MEP thresholds.   
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Figure 5.1 Experimental design 
 
The experiment was designed (A) to study the response to rPAS before, 1 
month and 3 months after BT injections. (B) In each session we measured: i) 
M1 excitability (AMT, RMT, 1mV-MEP and IO curve), ii) intra-cortical excitability 
(SICI and ICF) and iii) SAI and LAI.  All measurements were repeated before 
rPAS, 0, 30 and 60 min after rPAS, except for the AMT and IO curve, which 
were measured only before rPAS. 
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5.3.4 Statistical Analysis 
 
To test if the subjects with arm involvement had different responses to rPAS 
than the patients with isolated CD, we first used a preliminary 3- way ANOVA 
(ARM INVOLVEMENT x BT INJECTIONS x rPAS).  Then, we used repeated 
measures ANOVA to determine the interaction between BT injections and our 
measures of interest: baseline measures of cortical excitability (including IO 
curves), response to rPAS, SICI, ICF, SAI and LAI. The clinical effect of BT 
injections was assessed by non-parametric Friedman’s ANOVA. We also 
correlated the rPAS response at 30min (as a % of the pre rPAS MEP amplitude) 
in the first session with patients’ demographic characteristics, using Spearman’s 
correlation analysis. In addition, a correlation analysis was performed between 
normalised rPAS response at 30min (since the response peaked at 30 min) in 
the first, second and third session and the time elapsed since the previous BT 
injections (in weeks) and BFM score. Since in this analysis within subjects 
repeated measures are combined, the correlation coefficient was calculated 
according to the Bland and Altman correction (Bland and Altman, 1995). 
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5.4 Results 
 
5.4.1 Clinical effect of BT injections 
As expected, there was a clinical improvement of dystonia after BT injections 
(Friedman’s χ2 (2) =10.8, p<0.01). Post hoc analysis showed that the BFM score 
was significantly lower (indicating less severe dystonia) 1 month after injections 
than  before and 3 months after BT injections (p< 0.01),  while no significant 
difference was found in BFM score before and 3 months after BT injections. 
 
5.4.2 BT injections into neck muscles do not modify baseline cortical-
spinal excitability 
 
BT did not change the RMT or AMT of the APB muscle. A two-way ANOVA 
comparing the MEP IO curve before rPAS in each of the three experimental 
sessions showed a significant effect of STIMULUS INTENSITY (F (2, 14) = 
41.15; p<0.01) but no effect of BT INJECTIONS and no STIMULUS INTENSITY 
x BT INJECTIONS interaction (Figure 5.2 ). Further analysis of the IO curve in 
the range of intensities from 90 to 110 % of 1mV MEP, which correspond to the 
range of MEP amplitudes before and after rPAS in all 3 experimental sessions, 
confirmed that there was a main effect of STIMULUS INTENSITY, but no effect 
of BT INJECTIONS or interaction INTENSITY X BT INJECTIONS. 
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Figure 5.2 Effect of BT injections on the IO curve 
 
There is no significant effect of BT injections on the IO curve.  
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5.4.3 BT injections reduce rPAS response in APB and FDI muscles 
 
The results on the effect of BT injections on the response to rPAS are illustrated 
in Figure 5.3. Patients with additional arm involvement (6/12) did not differ from 
patients with isolated CD (6/12) in response to rPAS in any of the 3 
experimental sessions. Therefore, all the subsequent analysis was done on the 
group of patients as a whole. 
 
For the APB muscle, a two way ANOVA revealed a significant effect of BT 
INJECTIONS (3 levels : before BT, 1 month and 3 months after BT) (F (2, 22) 
=6.46; p<0.01) and rPAS ( 4 levels: before rPAS, 0min, 30min and 60min after 
rPAS) (F (3, 33) =3.66; p<0.05) as well as a significant interaction (F (6, 66) 
=3.06; p<0.01) ). Post hoc analysis showed for the factor BT INJECTIONS that 
the mean MEP amplitude was lower one month after BT injections comparing to 
the values before BT injections and 3 months after injections (p<0.01). Post hoc 
analysis for the main factor rPAS showed that the mean MEP amplitude was 
significantly higher 30 min after rPAS, comparing to the other time points (p< 
0.05). The BT INJECTIONS X rPAS interaction was further explored by 
examining the main effect of rPAS separately within each experimental session. 
This showed a significant effect of rPAS before BT injections (F (3, 33) = 4.86, 
p<0.01) but not after 1 month (F (3, 33) = 0.18, p>0.05), nor after 3 months (F 
(3, 33) = 1.85, p>0.05). There was a non-significant trend for rPAS response to 
be greater at 3 months post BT compared to 1 month post BT. 
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In the FDI muscle ANOVA revealed a significant effect of BT INJECTIONS (F 
(2.22) = 7.60; p<0.01) while rPAS or interaction BT INJECTIONS X rPAS were 
non-significant. Similarly to the APB muscle, the mean FDI MEP amplitude after 
rPAS was lower one month after BT (p<0.01) compared to the values before 
BT, but no different from the value at 3 months. 
 
To compare whether the APB and the FDI behaved similarly in response to 
rPAS and BT, (Quartarone et al., 2003, Quartarone et al., 2008) for each 
individual we expressed the average facilitation at 0, 30 and 60 min after rPAS 
as a percentage of the corresponding baseline values. A two way ANOVA with 
main factors  MUSCLE (APB and FDI) and BT INJECTIONS revealed a 
significant effect of BT INJECTIONS (F (2, 22) =4, 04; p<0.05) but not of 
MUSCLE or interaction MUSCLE X BT INJECTIONS . We conclude that 
response to rPAS in relation to BT injections was similar in the APB and FDI 
muscles.  
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Figure 5.3 Effect of BT injections on the rPAS response 
 
Botulinum toxin injections into dystonic neck muscles abolished the rPAS 
induced plasticity of the primary motor cortex hand area. Before BT injections 
(A) rPAS induced powerful plastic changes of hand cortical-spinal excitability: 
MEPs in APB and FDI muscles increased in amplitude immediately after rPAS 
(0 min), reaching a peak at 30 min. One month after BT injections (B) the rPAS 
response was completely abolished and it partially recovered three months later 
(C).   
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5.4.4 rPAS and BT do not modify intracortical excitability and sensory 
afferent inhibition from hand muscles 
 
There was no effect of rPAS or BT injections on SICI and ICF. 
There was no effect of rPAS or BT injections on SAI and LAI (Figure 5.4). 
 
 
 
Figure 5.4 Effect of rPAS and BT injections on SAI and LAI 
 
Patients with CD showed no short afferent inhibition (SAI) at an ISI of 25 ms 
(A), while long afferent inhibition (LAI) was present (B). Transmission in both 
SAI and LAI circuits was not modulated by BT injections or by rPAS. 
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5.4.5 rPAS induced plasticity correlates with dystonia severity and time 
after previous BT treatment 
 
There was a significant positive correlation between the normalized MEP 
amplitude at 30 min after rPAS and (i) the time elapsed after BT injections 
(R2=0.37, p<0.01) and (ii) the severity of dystonia assessed by BFM score 
(R2=0.30 p<0.01) (Figure 5.5). There were no significant correlations between 
patients’ age, disease duration, duration of BT treatment or the dose of the last 
BT injections and the rPAS response. 
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Figure 5.5 Correlation between rPAS induced plasticity of the primary 
motor cortex and timing of previous BT injection or clinical symptoms of 
dystonia. 
 
Peak-to-peak amplitude of the normalised APB MEPs recorded 30 min 
after rPAS positively correlated with (A) the time elapsed since the 
previous BT injections in weeks and with (B) the Burke-Fahn-Marsden 
dystonia severity score. Each patient with their corresponding values of 
rPAS response and the number of weeks since the previous BT 
injections (A) or BFM score (B) is plotted 3 times -before BT injections, 
1month and 3 months after BT injections.  
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5 5 Discussion 
 
BT transiently abolished the response to an experimental sensorimotor plasticity 
protocol in patients with CD. Before BT injections, rPAS significantly facilitated 
MEP amplitude in the hand muscles. One month after injections this facilitation 
was suppressed, while at 3 months it partially recovered. The response to rPAS 
correlated significantly with the time elapsed after previous BT injections and 
with the clinical severity of dystonia as measured by BFM total score. We saw 
no clinical improvement in the severity of arm dystonia in those patients with CD 
with additional arm involvement, after injections into the neck muscles. 
 
Possible BT action on the mechanism of cortical plasticity 
 
BT can affect the release of neurotransmitters that are important for brain 
plasticity and is used in animal studies to block the connection between different 
brain areas, in order to study changes in brain plasticity (Ando et al., 2002, 
Costantin et al., 2005, Caleo et al., 2007) .  Although there is some evidence to 
support hematogenous and axonal spread of large doses of BT in animals 
(Boroff and Chen, 1975, Antonucci et al., 2008) similar evidence in humans is 
lacking. Therefore a direct central effect of BT on plasticity in our patients is 
unlikely, particularly at the doses used for treatment of dystonia. 
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Another explanation for our results is that the effect of BT on cortical plasticity 
may be secondary to changes in the motor maps that occurred after afferent 
input from cervical muscles was altered by injections (Byrnes et al., 1998, 
Thickbroom et al., 2003). A considerable body of evidence demonstrates the 
importance of afferent input in modulating both cortical organization and its 
excitability (Brasil-Neto et al., 1992, Ridding and Rothwell, 1995, Ziemann et al., 
1998a, Ziemann et al., 1998b).  In dystonia, changes in “motor maps” of the 
hand muscles have been described after BT injections (Byrnes et al., 1998, 
Thickbroom et al., 2003). Thickbroom et al. (2003) reported that in patients with 
CD, motor maps of the APB are displaced in the hemisphere contralateral to the 
direction of head rotation. After BT injections into cervical muscles, the APB 
motor maps reverted to a more normal position, thus showing that changes in 
the motor cortical topography after injections may extend outside the area  
representing the treated muscles. This may be relevant for the experimental 
plasticity protocol we used. PAS relies on the interaction between sensory 
afferents and the motor output of the homologous muscle. If motor maps 
change in location after BT, then there may be a degree of disconnection 
between the sensory afferents and the altered location of the hand motor maps 
leading to a reduced PAS response as measured in the hand muscles.
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Measures of sensorimotor cortical inhibition and their relation to BT 
injections and rPAS 
 
LAI was present in our group of dystonia patients, and was not modified with 
rPAS or in relation to BT injections (Figure 5.4 B). However, the SAI at an ISI of 
25 ms was absent and was not modified after rPAS (Figure 5.4 A). We 
measured SAI at an ISI of 25ms based on previous data on healthy subjects 
from Quartarone et al. (2006a), who found that SAI at 25ms ISI is present and 
may be modulated by rPAS. When Kessler et al. (2005) studied SAI in patients 
with writer’s cramp at ISIs ranging from 14 to 36 ms the strongest inhibition was 
present at an ISI of 20 ms. Therefore, it is possible that we may have missed 
SAI at shorter intervals. Alternatively, our findings of absent SAI in CD patients 
(while not the main objective of this study) might reflect an abnormality in 
afferent inhibition in CD. 
 
Limitations of the study 
 
We did not record the H reflex or F-waves to monitor possible changes in α 
motoneuron excitability secondary to BT. However, we did not find any effect of 
BT on RMT, AMT and IO curves, i.e. in parameters which test the excitability of 
the entire corticospinal tract including the α  motoneuron. In line with our 
observations, Priori et al.(Priori et al., 1995) found that 1 month after BT 
injections to the arm, the Hmax:Mmax ratio is unchanged, thus suggesting that 
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BT does not affect α  motoneuron excitability. We found that BT injections 
reduce cortical plasticity in chronically treated dystonia patients, but we cannot 
comment on whether a similar effect would be present in dystonia patients 
naïve to BT. Another limitation of the study is the lack of comparison with 
healthy controls. However, a number of previous studies on different forms of 
dystonia, including CD, have demonstrated that dystonia patients have 
abnormally enhanced responses to PAS protocols compared to normal subjects 
(Quartarone et al., 2003, Weise et al., 2006, Quartarone et al., 2008). Our 
primary interest was to assess the change in PAS response with BT injections 
rather than the absolute level of PAS response at baseline. In the context of this 
study we consider that a comparison group of CD patients treated with placebo 
injections or a healthy participant group given BT injections would not have 
been justified ethically. 
 
Conclusion 
 
BT injections into dystonic neck muscles decreased sensorimotor associative 
plasticity in the hand area in patients with CD. We propose that this central 
effect is mediated by changes in motor maps, caused by reduced afferent input 
from the neck muscles following injections. Modulation of sensorimotor plasticity 
by changing the afferent input from the dystonic muscles may perhaps 
contribute to the clinical benefit of BT injections in dystonia over and above the 
effects caused by weakness in the injected muscles.   
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 Pathophysiological differences Chapter 6
between secondary and primary dystonias: 
the roles of cortical plasticity and 
intracortical inhibition 
 
Primary dystonia is thought to be a disorder of the BG because the symptoms 
resemble those of patients who have anatomical lesions in the same regions of 
brain (secondary dystonia). However, these two groups of patients respond 
differently to therapy suggesting differences in the pathophysiological 
mechanisms. In the following experiments we investigated if primary and 
secondary dystonia share the same pattern of electrophysiological 
abnormalities. We used TMS to study cortical functional involvement and the 
eye-blink classical conditioning paradigm to assess cerebellar functional 
involvement. 
 
The work presented in this Chapter is published in the form of a research 
article: Kojovic M, Pareés I,  Kassavetis P, Palomar FJ,  Mir P, Teo JT,  
Cordivari C, Rothwell JC, Bhatia KP and. Edwards MJ .Secondary and primary 
dystonia: pathophysiological differences. Brain. 2013 Jul;136(Pt 7):2038-49. 
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6.1 Summary 
 
Pathophysiological deficits in primary dystonia are well characterised and 
include reduced inhibition at many levels of the motor system and increased 
plasticity, while emerging evidence suggests there are additional cerebellar 
deficits. We compared the electrophysiological features of primary and 
secondary dystonia, using TMS of the motor cortex and the eye blink classical 
conditioning (EBCC) paradigm, to test whether dystonic symptoms share the 
same underlying mechanism. 11 patients with hemidystonia caused by BG or 
thalamic lesions were tested over both hemispheres, corresponding to the 
clinically affected and non-affected side and were compared to ten patients with 
primary segmental dystonia with arm involvement and ten healthy participants 
of similar age. We measured RMT, AMT, IO curve, SICI and CSP. Plasticity 
was probed using PAS 25. In secondary dystonia cerebellar-dependent 
conditioning was measured using the EBCC paradigm and results were 
compared to the data obtained from primary dystonia patients previously in our 
lab using the same technique. We found no difference in the MTs, IO curves or 
CSP between the secondary and primary dystonia patients or the healthy 
controls. In secondary dystonia SICI was reduced on the affected side, while it 
was normal on the non -affected side. Secondary dystonia patients had a 
normal response to the plasticity protocol on both affected and non-affected 
side and a normal EBCC that was not different from healthy participants. In 
contrast, patients with primary dystonia showed increased cortical plasticity and 
 136 
 
reduced EBCC. Normal motor cortex plasticity in secondary dystonia 
demonstrates that abnormally enhanced cortical plasticity is not required for 
clinical expression of dystonia, and the normal EBCC suggests an absence of 
functional cerebellar involvement in this form of dystonia. Reduced SICI on the 
side of the lesion may result from abnormal BG output or be a consequence of 
maintaining an abnormal dystonic posture. Dystonia appears to be a motor 
symptom that can reflect different pathophysiological states triggered by a 
variety of insults. 
 
6.2 Introduction 
 
Dystonia is a hyperkinetic movement disorder characterised by sustained 
muscle contraction leading to twisting, repetitive movements and abnormal 
postures of affected body parts (Fahn, 1988). In the absence of any 
pathological cause, Marsden et al. (1985) initially proposed that primary 
dystonia was a BG disease on the basis that the symptoms closely resembled 
those of some patients with identified lesions of the BG or their output pathways 
(now classified as secondary dystonia). The implication was that the similarity of 
symptoms was caused by a similar underlying pathophysiology. However, 
primary and secondary dystonias differ in their response to treatment (Neychev 
et al., 2011); in addition there is emerging evidence that a cerebellar deficit may 
contribute to the symptoms of primary dystonia (Sadnicka et al., 2012) .Given 
the etiological and clinical heterogeneity of dystonia, the aim of the present 
 137 
 
study was to test whether the primary and secondary forms share a similar 
pathophysiological mechanism. 
 
Most electrophysiological and neuroimaging studies in dystonia have been 
conducted on patients with primary dystonia since this is the commonest form of 
the condition (Bressman, 2004). A consistent finding is loss of inhibition at 
different levels of the CNS, including spinal cord, brainstem and motor cortex 
(Berardelli et al., 1985, Nakashima et al., 1989, Ridding et al., 1995b). Recent 
evidence from human studies suggests that abnormally enhanced synaptic 
plasticity is also an important factor in the pathophysiology of the primary 
dystonias (Peterson et al., 2010, Quartarone and Pisani, 2011). Patients with 
primary focal and primary generalised dystonia have an abnormally enhanced 
response to different plasticity protocols that probe LTP-like and LTD-like 
synaptic plasticity in the motor cortex (Quartarone et al., 2003, Edwards et al., 
2006, Weise et al., 2006, Gilio et al., 2007, Quartarone et al., 2008) or 
brainstem circuits (Quartarone et al., 2006b). Finally, a range of recent evidence 
from structural and functional imaging and electrophysiology (Teo et al., 2009) 
suggests that the cerebellum may also play some role in primary dystonia. 
Thus, voxel based morphometric studies have found grey matter changes in the 
cerebellum of patients with focal dystonias (Draganski et al., 2003, Delmaire et 
al., 2007, Obermann et al., 2007), functional MRI has revealed changes in 
movement-related activity (Odergren et al., 1998, Carbon and Eidelberg, 2009) 
and metabolic profile (Hutchinson et al., 2000). 
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Although there are some reports that patients with secondary dystonia may 
share similar abnormalities in inhibitory networks of the motor system 
(Nakashima et al., 1989, Trompetto et al., 2012), there is no information about 
plasticity or cerebellar function in this group of patients. The aim of the present 
study was to provide a more comprehensive comparison of the underlying 
pathophysiology in primary and secondary dystonias. The results show that 
there are distinct differences in physiology, implying that the clinical syndrome 
of dystonia has more than one physiological phenotype. This would be 
consistent with the fact that dystonia can have many different causes and can 
respond quite differently to treatment (Neychev et al., 2011). The conclusion is 
that dystonia represents one (of many) possible stable state(s) into which the 
motor system can be pushed through a variety of insults. 
 
6.3 Methods 
 
6.3.1 Participants 
 
We studied 11 patients with secondary dystonia caused by a structural brain 
lesion (5 men and 6 women, mean age 45.8 years, range 28-68, Table 6.1), 10 
patients with primary segmental dystonia (4 men and 6 women, mean age 46.7 
years, range 31-67, Table 6.2) and 10 age -matched healthy participants (5 
men and 5 women, mean age 48.7 years, range 27-67). Patients with 
secondary dystonia were included if they had: (i) unilateral distribution of 
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dystonia (ii)a discrete  lesion in the BG and/or thalamus contralateral to the 
clinically involved side on magnetic resonance imaging or computed 
tomography and (iii) no significant pyramidal involvement or hemisensory loss, 
as assessed by the Ashworth scale and NIH Stroke Scale. All patients were 
clinically examined and videotaped. Three patients with secondary dystonia had 
resting dystonia with fixed postures (patient 1 and 2 fixed dystonia of the  leg, 
patient 5 fixed dystonia of the arm), the other eight patients had mobile dystonia 
at rest, worsened by action. All patients with primary dystonia had segmental 
dystonia with unilateral arm involvement visible at rest or on maintaining an 
outstretched arm. Clinical disease severity was assessed with Burke-Fahn-
Marsden (BFM) scale.  All patients treated with BT were injected at least 15 
weeks before participating in the study. One of the secondary dystonia patients 
(patient 5) had undergone unilateral thalamotomy 20 years earlier, with only 
transient improvement of symptoms.  At the time of the study, none of the 
participants were on any medications that we believe could affect the 
measurements performed. All the participants were right-handed.  EBCC testing 
was performed on patients with secondary dystonia and, for convenience their 
data on EBCC were compared to the data of primary dystonia patients ( 7 
males, 6 fames, mean age 63.7 +/- 3.4 (SEM)) and healthy participants (6 
males, 5 females, mean age 61 +/- 4.5 (SEM))  obtained in our laboratory using 
the same experimental protocol (Teo et al.,2009). 
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Table 6.1 Clinical and demographic characteristic of secondary dystonia patients 
Patient Age(yrs) 
/Gender 
Dystonia 
onset 
(yrs) 
Disease 
duration 
(yrs) 
Distribution of 
dystonia and 
characteristics 
Cause Lesion on 
MRI 
BFM 
score 
 
NIHSS 
score 
Duration of BT 
treatment (yrs) 
1 38/F 28 10 L hemidystonia; fixed 
at foot, mobile at arm 
Ischemic 
stroke 
R pallidum 9 0 2 (Discontinued In last 
4 yrs) 
2 63/F 32 29 L hemidystonia; fixed 
at foot, mobile at arm 
Ischemic 
stroke 
R striatum 21 2 Not treated 
3 40/M 2 38 R hemidystonia; 
mobile 
Perinatal HII L thalamus 28 1 5 
4 68/M 55 13 R hemidystonia; 
mobile 
Ischemic 
stroke 
L thalamus 18 1 Not treated 
5 63/F 2 61 L hemidystonia; fixed 
at arm, mobile at leg 
Perinatal HII R lent.nc. 27 2 15 
6 38/M 6 32 L hemidystonia; 
mobile 
Ischemic 
stroke 
R lent.nc. 16 2 Not treated 
7 28/M 2 26 L  arm; mobile Perinatal HII R lent.nc. 19 3 6 
8 36/F 3 33 L hemidystonia; 
mobile 
Encephalitis R lent. nc. 27.5 1 7 
9 48/F 1 47 L hemidystonia; 
mobile 
Perinatal HII R lent. nc. 21.5 0 18 
10 42/M 18 24 R hemidystonia; 
mobile 
Ischemic 
stroke 
L striatum 26 2 10 
11 40/F 1 39 R hemidystonia; 
mobile 
Perinatal HII L lent. nc. 13 0 Not treated 
Average 
+/- SE 
45.8 
+/-13.8 
13.6 
+/-4.1 
32 
+/-9.6 
   20.5 
+/-6.2 
1.3 
+/-0.4 
5.7 
+/-1.7 
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 Table 6.2 Clinical and demographic characteristic of primary dystonia patients 
Patient Age(yrs) 
/Gender 
Age of dystonia 
onset 
Disease 
duration(yrs) 
Distribution of dystonia and 
characteristics 
BFM 
score 
Duration of  BT 
treatment (yrs) 
1 39/F 29 10 CD and R arm dystonia 12 5 
2 63/F 59 4 BSP, CD and R arm dystonia 13 2 
3 29/F 23 6 CD and R arm dystonia 
 
9 Not treated 
4 44/M 40 4 CD and L arm dystonia 8 2 
5 31/M 24 7 CD and R hand dystonia  8 Not treated 
6 53/F 47 6 Laryngeal dystonia, CD and L arm 
dystonia 
26 6 
7 40/F 32 8 CD and R arm dystonia 12 2 
8 67/M 20 47 Laryngeal dystonia and L arm 
dystonia, L dystonic  tremor 
9 26 
9 50/M 43 7 CD and R hand dystonia 
 
16 5 
10 51/M 29 10 BSP, CD and R arm dystonia 9 5 
Average 
+/- SE 
46.7 
+/-14.8 
34.6 
+/-10.9 
10.9 
+/-3.4 
 12.2 
+/-39 
5.3 
+/-1.7 
Abbreviations: yrs: years; BFM: Burke-Fahn-Marsden dystonia score; BT: Botulinum Toxin; F: Female; M: Male; BSP, 
blepharospasm; CD, cervical dystonia; R: Right; L: Left 
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6.3.2 EMG recordings and TMS 
 
EMG recordings were made from the APB and ADM on the side contralateral to 
the stimulated hemisphere. We used single-pulse and paired-pulse TMS and 
PAS25 protocol, as indicated in Chapter 2. SICI was assessed at an ISI of 2 
ms. 
 
6.3.3 Eye blink classical conditioning (EBCC) 
An electrical stimulus was applied through a bipolar electrode, with the cathode 
positioned proximally. The electrical stimuli were constant current square wave 
pulses with a pulse width of 200 µs, i.e. unconditioining stimulus (US) and were 
delivered to the right supraorbital nerve at an intensity adjusted to obtain stable 
R2 responses (approximately 4-6 times the sensory threshold).  Electrical 
supraorbital nerve stimulus was preceded by a tone, i.e. the conditioning 
stimulus (CS), produced by a tone generator and presented bilaterally to the 
subject via binaural headphones at an intensity 50–70 dB above the individual 
hearing threshold. The CS intensity was kept constant during experiment. The 
CS inconsistently produced an acoustic startle response (alpha blink) occurring 
within 200 ms after the CS onset. Repeated pairs of CS and US at 400 ms 
intervals induced a conditioned eye blink response (CR) to appear with onsets 
within 200 ms before US. EBCC sessions consisted of seven blocks: six 
acquisition blocks (each block contained 11 trials in: nine trials of CS–US pairs, 
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the 10th trial was US only and trial 11th was CS only) followed by one extinction 
block (11 trials of CS only). For measurement of EBCC, the CRs were counted 
manually. EMG bursts were regarded as ‘‘alpha blinks’’ if their amplitude 
exceeded 50 µV and if latency was < 200 ms after the CS. EMG bursts were 
regarded as CRs if latency was > 200 ms after the CS but before the US . For 
the CS only trials, EMG bursts occurring 200–600 ms after the CS were 
considered CR. 
 
6.3.4 Experimental design 
 
Secondary dystonia patients were tested on both hemispheres, corresponding 
to the clinically affected and non-affected side in two different TMS sessions, 
separated by at least one week (Figure 6.1). The order of the tested 
hemisphere (affected vs. unaffected) was balanced between subjects. Primary 
dystonia patients were tested on the hemisphere corresponding to the affected 
side only, since previous studies had showed that in primary dystonia 
abnormalities in TMS measures are present in the affected and unaffected parts 
of the body (Quartarone et al., 2008). Healthy participants were tested on the 
dominant hemisphere only. In each session we began with baseline 
assessments of RMT, AMT and 1mV- MEP, IO curve, SICI and CSP. We then 
delivered PAS25 and assessed the effect of this conditioning protocol on 
corticopinal excitability (1mV- MEPs) at three different time points: 0, 15 min 
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and 30 min after PAS. In addition, secondary dystonia patients underwent a 
third session for EBCC testing.   
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Figure 6.1 Experimental design 
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6.3.5 Statistical analysis 
 
ANOVA was used to test the age differences between secondary dystonia 
patients, primary dystonia patients and healthy controls. The differences in 
disease duration, BFM scores and duration of BT treatment between secondary 
and primary dystonia patients were assessed with Mann-Whitney U test. 
The primary aim of this study was to compare the TMS parameters between the 
affected side in secondary dystonia patients and primary dystonia patients and 
healthy participants. RMT, AMT, EMG root square amplitude, SICI and CSP 
were compared between groups using ANOVAs with a factor GROUP (3 levels: 
secondary dystonia-affected side, primary dystonia and healthy participants) as 
a between-subject factor. For analysis of SICI, conditioned MEP amplitudes 
were averaged, normalized to average unconditioned MEP amplitudes and 
entered into ANOVA with factor GROUP as between-subjects factor. IO curves 
were compared between groups in ANOVA with the factor GROUP and the 
factor STIMULUS INTENSITY (10 levels of stimulator output intensity ranging 
from 80 % to 170% of RMT intensity) as a within-subjects factor. For analysis of 
the PAS effect, MEP amplitudes at each time point were averaged, normalized 
to baseline MEPs and entered into ANOVA with factor GROUP as between-
subjects factor and factors  MUSCLE (2 levels: APB and ADM muscle)  and 
TIME POINT  (3 levels: 0 min, 15 min and 30 min after PAS) as a within-
subjects factors. As a secondary analysis, we assessed how TMS measures 
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compared between the affected and non-affected side in secondary dystonia 
patients, using repeated measures ANOVA or paired sample t-test.  For EBCC, 
the percentage of CRs over different blocks did not follow the normal 
distribution, therefore non-parametric tests were used. We first compared the 
number of overall CR ( for all blocks) in each group using Kruskal -Wallis 
ANOVA. The differences in the number of CR in each block between groups 
were then assessed by Mann-Whitney U test. Finally, for each group we used 
Friedman ANOVA to test if there was a conditioning of eye blink responses 
across blocks. 
 
Possible correlations between clinical and demographic data (disease duration, 
BFM score, duration of BT injection treatment) and TMS measures (SICI, 
averaged PAS response) were evaluated with the Spearman correlation 
analysis. 
 
6.4 Results 
 
6.4.1 Clinical and demographical data 
 
There was no significant difference in age between the secondary and primary 
dystonia patients and healthy participants. As expected, the BFM score was 
higher in the secondary compared to primary dystonia patients (z=-2.9; 
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p=0.004) and also the disease duration was longer in the secondary dystonia 
patients (z= -3.14; p=0.002). No difference was found in the duration of BT 
treatments between the dystonia groups (z=-0.72; p=0.93). 
 
6.4.2 Corticospinal excitability and EMG root mean square amplitude 
 
At baseline, no significant difference was found in RMT, AMT, 1mV MEPs TMS 
intensity or EMG root mean square amplitude between secondary dystonia and 
primary dystonia patients and healthy participants or between affected and non- 
affected sides in secondary dystonia patients. 
 
As expected, for IO curves ANOVA showed a significant effect of STIMULUS 
INTENSITY (F (9, 207) =28.9; p < 10-3), due to an increase of MEP size with 
increasing TMS intensity, while the factor GROUP and the interaction GROUP 
X STIMULUS INTENSITY were both non-significant. The side comparison in 
secondary dystonia, also revealed a significant effect of STIMULUS INTENSITY 
(F (9, 36) =13.6; p < 10-3while the main factor SIDE and the interaction SIDE X 
STIMULUS INTENSITY were both non- significant. These results overall 
indicate that there was no difference in baseline corticopinal excitability between 
secondary dystonia and primary dystonia patients and healthy participants 
(Figure 6.2) or between affected and non-affected sides  in secondary dystonia 
patients (Figure 6.3).  
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Figure 6.2 IO curves 
 
The IO curves in secondary dystonia patients, primary dystonia patients and 
healthy participants are not significantly different.  
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Figure 6.3 IO curves in affected and non-affected side in secondary 
dystonia patients 
 
There is no difference in the IO curves between the affected and non-affected 
sides of secondary dystonia patients. 
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6.4.3 SICI 
 
ANOVA revealed a significant effect of factor GROUP (F (2, 27) =5.11; p = 
0.01), due to less SICI in secondary dystonia patients compared to healthy 
participants (p=0.01), while there was no difference between primary and 
secondary dystonia or between primary dystonia and healthy participants. 
When the affected side was compared to the non-affected side in secondary 
dystonia, a paired-sample t-test revealed significant difference (p=0.02) due to 
less SICI on the more affected side (Figure 6.4). 
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Figure 6.4 Short-interval intracortical inhibition 
 
In secondary dystonia patients, SICI is reduced on the affected side, compared 
to the non-affected side and to healthy participants. Data is plotted as a ratio to 
the unconditioned MEP amplitude. (** p ≤0.01; *p<0.05)  
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6.4.4 CSP 
 
ANOVA revealed no difference in CSP between secondary dystonia and 
primary dystonia patients and healthy participants. Also paired-sample t-test 
revealed no difference in CSP between affected and non-affected sides in 
secondary dystonia (Figure 6.5). 
 
 
 
Figure 6.5 Cortical Silent Period 
 
There is no difference in the CSP duration between secondary dystonia 
patients, primary dystonia patients and healthy participants.  
 154 
 
6.4.5 PAS 
 
There was no within-or between-subject difference in electrical stimuli counting 
errors during PAS, thus excluding differences in attention levels in different 
sessions. 
 
The results of PAS effect are given in Figures 6.6, 6.7 and 6.8. Figure 6.9 
represents averaged PAS response in individual participants. ANOVA revealed 
significant effect of the factor GROUP (F (2, 28) =12; p < 10-3), due to higher 
response to PAS in primary dystonia patients comparing to both secondary 
dystonia patients (p < 10-3) and healthy participants (p < 10-3), while there was 
no difference between secondary dystonia patients and healthy participants. 
Factors MUSCLE and TIME POINT were not significant and  all 2 -way and 3-
way interactions were also not significant, indicating that PAS response was 
higher in primary dystonia at all 3 time points after the PAS and in both APB 
and ADM muscles (Figure 6.6 and 6.7). When the affected side was compared 
to non-affected side in secondary dystonia, ANOVA revealed the significant 
effect of the factor MUSCLE (F (1, 9) =8.7; p=0.02), due to higher response to 
PAS in the APB compared to the ADM muscle. Factors SIDE and TIME POINT 
were not significant as were  the interactions between main factors, indicating 
that there was no difference in the PAS response between the affected and 
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non-affected side in secondary dystonia and that there was no spread of the 
PAS effect to the ADM muscle on either side (Figure 6.8.). 
 
 
 
Figure 6.6 PAS effect on corticospinal excitability, as measured by change 
in 1mV MEP amplitude in APB 
 
In the APB muscle, primary dystonia patients  have a higher response to PAS at 
all 3 time points (i.e. 0 min, 15 min and 30 min after PAS) compared to 
secondary dystonia patients and healthy participants( ** p ≤0.01). There is no 
difference in PAS response between the secondary dystonia patients and 
healthy participants.  
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Figure 6.7 PAS effect on corticospinal excitability, as measured by change 
in 1mV MEP amplitude in ADM 
 
Primary dystonia patients have a spread of PAS effect in the non-median 
innervated ADM muscle (** p ≤0.01), that is not present in secondary dystonia 
patients or healthy participants.  
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Figure 6.8 PAS response on affected and non-affected side in secondary 
dystonia patients 
 
There is no difference in the PAS response between the affected and non-
affected side in secondary dystonia patients. On both the affected and non-
affected side, the PAS response is larger in the APB compared to ADM muscle 
(* p ≤0.05).  
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Figure 6.9 Averaged PAS response in individual participants. 
 
For each participant, the PAS response is expressed as an averaged MEP 
amplitude for 3 time points after PAS (0 min, 15 min and 30 min after PAS) and 
is plotted on y-axis. For secondary dystonia the data refer to the affected side.  
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Table 6.3 Statistics of Eye-blink Classical Conditioning (Mann-Whitney U tests) 
 
 
 Block 1 
 
Block 2 Block 3 Block 4 Block 5 Block 6 
Secondary 
Dystonia 
vs. 
Primary 
Dystonia 
Z=-0.90 
p=0.4 
Z=-2.05 
p=0,04 
Z=-2.54 
P=0.01 
Z=-3.19 
P=0.001 
Z=-2.93 
P=0.003 
Z=-.62 
P=0.009 
Secondary 
Dystonia 
vs. 
Healthy 
Participants 
Z=-0.74 
P=0.5 
Z=-1.77 
P=0.08 
Z=-1.15 
P=0.2 
Z-=0.76 
P=0.5 
Z=-0.36 
P=0.7 
Z=-0.96 
P=0.3 
 
Primary 
Dystonia 
vs. 
Healthy 
Participants 
Z=-1.71 
P=0.09 
Z=-0.27 
P=0.8 
Z=-1.18 
P=0.2 
Z=-2.49 
P=0.01 
Z=-2.74 
P=0.006 
Z=-2.41 
P=0.02 
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6.4.6 EBCC 
 
ANOVA revealed significant difference in the ages of the compared groups (F 
(2, 32) =5.9; p =0.006), because our secondary dystonia patients were younger 
than the historical primary dystonia controls (p=0.007) and healthy participants 
(p=0.03). 
Kruskal-Wallis ANOVA revealed a significant effect of the factor GROUP (χ2 (2, 
N = 34) = 10.2; p=0.006). Post-hoc Mann-Whitney U tests showed that that this 
was due to more CR  in the secondary compared to the primary dystonia in 
block 2-6 and more CR  in healthy participants compared to  primary dystonia 
patients (blocks 3-6) ( Table 6.3). There was however no difference between 
the secondary dystonia patients and healthy participants. We further confirmed 
with Friedman ANOVA that the number of CR increased over blocks in both 
secondary dystonia patients (χ2= 22.4; p<10-3) and healthy participants (χ2= 
22.9; p<10-3), but not in the primary dystonia patients (χ2= 3.53; p=0.6) (Figure 
6.10). 
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Figure 6.10 Eye Blink Classical Conditioning (EBCC) 
 
Patients with secondary dystonia have significantly more conditioned eye blink 
responses compared to primary dystonia patients. Note that the secondary 
dystonia patient’ data in the present study are compared to historical data from 
primary dystonia patients and healthy participants obtained in our laboratory 
using the same experimental protocol. 
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We found no significant correlation between the clinical and demographic data 
and TMS measures in our patients. 
 
6.5 Discussion 
 
The main findings of the present study are: (i) in secondary dystonia patients a 
response to PAS is no different than in healthy participants, in contrast to the 
enhanced response of patients with primary dystonia; (ii) secondary dystonia 
patients have reduced SICI, on the side of the lesion only; and (iii) EBCC is 
worse in patients with primary than in those with secondary dystonia. 
 
Differences in PAS induced plasticity between secondary and primary 
dystonia 
 
The enhanced response to PAS that we found in our patients with primary 
dystonia is in line with many previous studies using a variety of plasticity-testing 
protocols (Quartarone et al., 2003, Edwards et al., 2006, Weise et al., 2006). It 
was, however, surprising to find that the response to PAS was normal in 
secondary dystonia. This is unlikely to be due to differences in baseline 
corticospinal excitability, as the IO curves and motor thresholds were the same 
in all three groups that we studied. Nor is it likely to be a result of the longer 
duration and more severe dystonic symptoms in the patients with secondary 
dystonia. Although the present study only examined cases of primary segmental 
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dystonia, previous investigations from this laboratory have found enhanced 
responses to experimental plasticity protocols even in patients with primary 
generalised dystonia, whose symptoms began in childhood (Edwards et al, 
2006) and were so severe as to require  bilateral pallidal deep brain stimulation 
(Ruge et al, 2011). In addition, there was no correlation between disease 
duration and the response to PAS in our secondary dystonia patients. 
 
As we found in the study described in Chapter 5   , BT treatment can transiently 
reduce the response to PAS in patients with primary dystonia, which then 
returns to levels found before BT injection after a few months. Since all the 
present patients were studied at least 15 weeks after their last injection, this 
acute effect of BT is unlikely to have influenced the present results. 
Nevertheless, it is difficult to speculate on whether there might have been 
possible chronic effects of BT on motor cortex plasticity, as this has not been 
previously investigated. Several of the patients with secondary dystonia had 
been treated for many years and it is possible that this could have permanently 
reduced their PAS response and skewed the group data even though there was 
no difference in the mean duration of treatment in the primary and secondary 
cases. This seems unlikely to have been the case as there was no correlation 
between the duration of BT treatment and the response to PAS protocol. 
 
In the absence of other explanations, we suggest that enhanced motor cortex 
plasticity is an inherent, genetically determined trait (endophenotype) specific 
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for primary dystonia that predisposes some individuals to develop dystonia. As 
suggested by Quartarone et al .(2006c) this may result in an excessive 
tendency to form associations between sensory input and motor output, leading 
to dystonia, particularly under circumstances involving frequent repetition of 
specific movements . In contrast, secondary dystonia is believed to be related to 
functional changes in sensorimotor circuits following brain  injury (Burke et al., 
1980). The exact mechanism underlying the changes resulting in secondary 
dystonia and the anatomical regions in which they occur are not well 
understood but it may be that the principal pathological processes spare the 
function of the primary motor cortex.  Thus, using PET activation study 
Ceballos-Baumann et al.  (1995) showed that pattern of primary motor cortex 
activity differs between acquired hemidystonia and idiopathic torsion dystonia 
patients. Similarly, a combined fMRI and DTI study on a patient with 
hemidystonia caused by penetrating injury of caudate and lentiform nucleus 
showed that there was no significant functional reorganisation in the  primary 
motor cortex after injury (Werring et al., 1998). This would be consistent with 
our finding of a normal response to PAS in our patients. 
 
EBCC and its possible relation to PAS response in dystonia 
 
EBCC, as used in human studies, is a form of predictive learning that lesion 
studies have shown to depend on the integrity of the olivo-cerebellar circuit 
(Gerwig et al., 2007). Indeed, in healthy individuals, continuous theta burst 
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stimulation (cTBS) over cerebellum, which is thought to interfere with function in 
cerebellar circuits, abolishes EBCC (Hoffland et al., 2012). Previously we had 
found that EBCC was markedly reduced compared to healthy volunteers in 
patients with primary focal hand and/or cervical dystonia and had speculated 
that this was further evidence in favour of cerebellar involvement in primary 
dystonias (Teo et al., 2009). In the present study, our patients with secondary 
dystonia showed preserved EBCC that did not differ from that of healthy 
controls. EBCC decreases with age, (Finkbiner and Woodruff-Pak, 1991, 
Bellebaum and Daum, 2004) and therefore the age difference between the 
different groups could have been a confounding factor. However, even though 
our secondary dystonia patients were younger than both healthy controls and 
primary dystonia patients, their EBCC was similar to that of healthy controls and 
superior to EBCC in primary dystonia. Therefore, a younger age is unlikely to be 
a reason for the apparently normal EBCC in our secondary dystonia patients. 
The implication of our findings is that the pathophysiology of secondary dystonia 
is more localised than that of primary dystonia. 
 
Although EBCC and PAS are usually thought to test quite different circuits in 
different parts of the brain, there may be some connection between them that 
could potentially link the present results in primary and secondary dystonias. 
Recent work has shown that the response to some PAS protocols is modulated 
by inputs from the cerebellum; thus a disordered cerebellum could potentially 
lead to abnormal PAS. In healthy volunteers, the effect of a PAS25 protocol 
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(that is, with an interval of 25ms between median nerve and TMS pulse) is 
reduced or abolished by concurrent anodal direct current stimulation over the 
cerebellum or by preconditioning with excitatory intermittent theta burst 
stimulation (Hamada et al., 2012a); in contrast, preconditioning the cerebellum 
with cTBS enhanced PAS (Popa et al., 2012). Thus, the effect of motor cortex 
PAS25 depends on the functional state of the cerebellar output. 
 
From the data outlined above, the combination of enhanced response to PAS25 
and decreased EBCC in primary dystonia is similar to what occurs with 
cerebellar cTBS in healthy volunteers: EBCC is reduced and PAS25 plasticity 
increased. The conclusion is that a cerebellar disorder in patients with primary 
dystonia could contribute to their abnormal response to PAS. However, this is 
unlikely to be the whole story. The response to PAS21.5 (that is, PAS with a 
21.5ms interval between stimuli) is unaffected by cerebellar direct current 
stimulation (Hamada et al., 2012a) in healthy participants yet it is still enhanced 
in primary dystonias (Weise et al., 2006), suggesting that there is an intrinsic 
disorder of cortical plasticity in addition to any secondary influence from a 
disordered cerebellum. 
 
The role of reduced intracortical inhibition in dystonia 
The final finding of our study is that secondary dystonia patients had decreased 
SICI on the affected side. This is in line with recent finding of reduced SICI in 
patients with dystonia caused by lentiform nucleus lesions (Trompetto et al., 
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2012). Nevertheless, the pathophysiological significance of reduced intracortical 
inhibition in dystonia remains obscure (Berardelli et al., 2008). Reduced SICI is 
not specific for dystonia and is found in other BG diseases, including PD and 
Tourette syndrome (Ridding et al., 1995a, Ziemann et al., 1997) and is also 
found in clinically unaffected carriers of DYT1 gene mutations (Edwards et al., 
2003). Therefore, a loss of intracortical inhibition may be regarded as a non-
specific maladaptive change within the motor cortex, caused by chronically  
disorganised BG output. Our finding would fit into this hypothesis, since SICI 
was only abnormal on the clinically affected side of our patients with secondary 
dystonia.  It is also possible that reduced SICI arises as a consequence of 
maintaining an abnormal dystonic posture that could have triggered cortical 
reorganisation through aberrant afferent input (Espay et al., 2006). 
 
The present data showed only a non-significant trend towards reduced SICI in 
patients with primary dystonia. Other studies have also reported normal SICI in 
primary dystonia (Rona et al., 1998, Brighina et al., 2009). This probably reflects 
the enormous between-subject variability of intracortical inhibition present even 
in healthy subjects (Wassermann, 2002). 
 
There was no significant difference in the CSP duration between groups, 
although there was a tendency toward a shortening of the CSP on the affected 
side in both secondary and primary dystonia, compared to controls. The 
literature on CSP in dystonia has been less consistent than for SICI, with 
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studies reporting normal CSP  (Stinear and Byblow, 2005) or reduced CSP 
(Chen et al., 1997) or an abnormality was restricted to a specific task (Tinazzi et 
al., 2005). SICI and the CSP are thought to depend on GABAa and GABAb 
cortical interneurons respectively and therefore could be differentially affected 
by disease (Werhahn et al., 1999, Di Lazzaro et al., 2006, Hallett, 2011). This 
might explain the abnormal SICI and normal CSP in our secondary dystonia 
patients. Trompetto et al. (2012) suggested that CSP is reduced in secondary 
dystonia when the lesion is restricted to the striatum, while it might be normal if 
the lesion involves the pallidum or thalamus. We did not find the duration of 
CSP to be related to the anatomical site of the lesion. 
 
Limitations of the study 
 
We acknowledge the limitations of our study. Our sample of secondary dystonia 
patients is heterogeneous regarding etiology and anatomical site of the lesion. 
Although it is possible that different lesions could have different functional effect 
on the motor cortex plasticity, we believe this is unlikely given the similar 
response to PAS among all secondary dystonia patients, including the lack of 
spread into the non-target ADM muscle. Another limitation of our data is the 
long interval between the brain injury and the TMS study. With the present 
design, we cannot exclude the possibility that motor cortex plasticity was 
affected at the time of emergence of dystonia, and then over time has reverted 
to normal. This issue could be addressed in a prospective study that would 
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need to include a large number of patients, given that only a small proportion of 
patients with subcortical lesions will go on to develop dystonia. 
 
Conclusion 
 
We have demonstrated that primary and secondary dystonia do not share the 
same pattern of electrophysiological abnormalities. In secondary dystonia 
caused by structural brain lesions, the response to PAS is normal, and therefore 
abnormally enhanced sensorimotor cortical plasticity is not required for the 
clinical expression of dystonia. In addition, cerebellar function as measured by 
EBCC is not affected in secondary dystonia, indicating that functional 
involvement of cerebellum is not an universal feature of dystonia. Our findings 
may give some insight into why the stimulation-based therapeutic interventions 
which are thought to interfere with motor cortex plasticity, such as repetitive 
TMS and DBS, might not be as useful in secondary as in primary dystonia 
patients (Andrews et al., 2010, Vidailhet et al., 2012). Further exploration of the 
difference in pathophysiological mechanisms in different types of dystonias may 
have implications in selecting the most appropriate treatment among different 
alternatives and also for developing new therapeutic strategies. 
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 General Discussion and Chapter 7
Conclusion 
 
In the present series of studies TMS was used to investigate cortical 
pathophysiology in two common movement disorders, PD and dystonia. The 
sensorimotor cortex was not considered to be a passive translator of abnormal 
BG input into aberrant motor output, but rather as a place that could tune the 
various inputs it receives before providing a final output for movement. 
Importantly, it was considered that in each disorder, the sensorimotor cortex 
could take on a dynamic role, going through different levels of functional 
reorganisation depending on many factors including:  disease stage, disease 
type (i.e. primary vs. secondary dystonia) as well as the functional state of other 
nodes in the motor network such as the cerebellum and afferent input. With this 
approach, any changes in electrophysiological measures at the level of 
sensorimotor cortex could be viewed as either compensatory, maladaptive or as 
an epiphenomenon of no significance for the disease. This thesis concentrates 
on the changes the in response to experimental plasticity protocols, given the 
reputed role of brain plasticity in adaptation to various physiological and 
pathological inputs. 
 
It has been classically considered that sensorimotor cortical plasticity is reduced 
or absent in PD (Ueki et al., 2006, Udupa and Chen, 2013), while it is increased 
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in dystonia (Quartarone et al., 2003, Quartarone and Pisani, 2011). The present 
series of experiments provides evidence that this is not necessarily always the 
case. 
 
By using the natural model of clinical asymmetry in PD, we have shown that 
cortical plasticity changes from being increased early in the course of the 
disease (and perhaps in the preclinical stage), to being smaller than normal as 
the disease progresses further. Increased sensorimotor cortical plasticity 
probably represents a compensatory response, which slows down the 
appearance and progression of motor signs. This is suggested by the 
association between the decrease in interhemispheric asymmetry of the PAS 
response and decrease in motor asymmetry of disease. Thus, early in PD 
changes in cortical plasticity are probably adaptive. The reduced 
responsiveness of the sensorimotor cortex to plasticity protocols in advanced 
PD most likely reflects the deficit of dopamine, which is an important 
neuromodulator of both LTP and LTD. 
 
We have shown that increased plasticity is not a “sine qua non” of dystonias. 
Secondary dystonias caused by BG lesions do not manifest enhanced 
responses to experimental plasticity protocols. This has several implications. 
Firstly, enhanced plasticity is not a pathophysiological feature of all dystonias 
but may be a trait only of the primary dystonias. Secondly, changes in cortical 
plasticity are not needed for the clinical expression of dystonic symptoms 
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whether they arise as a consequence of cortical reorganisation secondary to 
abnormal BG output or are secondary to dystonic activity at the periphery, as 
suggested by normal plasticity in secondary dystonia patients.  Moreover, even 
when present, plasticity changes are not fixed but can be modified by 
manipulating various other inputs to the sensorimotor cortex. This explains why 
modifying afferent input with BT injections in cervical dystonia reduces excess 
plasticity. There are other examples in the literature demonstrating changes in 
plasticity with changes in BG cortical input after DBS of GPi (Tisch et al., 2007, 
Ruge et al., 2011). 
 
A second pathophysiological difference between secondary and primary 
dystonia is in the presence of cerebellar involvement. Cerebellar function as 
measured by EBCC is not affected in secondary dystonia caused by BG 
lesions, indicating that functional involvement of cerebellum is not a universal 
feature of dystonia. However, the on-going debate as to whether changes in 
cerebellar activity in primary dystonia are (a) compensatory or (b) an 
epiphenomenon occurring secondary to abnormal activity elsewhere within the 
sensorimotor network or (c) are a primary part of the pathophysiology of 
dystonia (Teo et al., 2009, Sadnicka et al., 2012) is still  not resolved. The 
compensation hypothesis is based on the idea that cerebellar hyperactivity, as 
seen in functional brain imaging of patients with primary dystonia can 
compensate for abnormalities in motor cortical plasticity. It is supported to some 
extent by the fact that in healthy subjects’ alterations of cerebellar activity using 
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transcranial direct current stimulation reduces responsiveness to a subsequent 
PAS protocol (Hamada et al., 2012b). In primary dystonia this compensatory 
activity may have deleterious effects on sensitive tests of cerebellar function, 
such as eye-blink conditioning, even though clinical signs of cerebellar 
dysfunction are absent. This would fit with our finding that since there are no 
abnormalities in motor cortical plasticity in secondary dystonia, there is no need 
for compensatory cerebellar activity, and thus EBCC is normal. Nevertheless, 
the data also could fit into the alternative hypothesis that cerebellar 
abnormalities are an intrinsic feature of primary dystonia, since they are absent 
in secondary cases. 
 
7.1. Further studies 
 
Though of interest in their own right, the findings here open up options for 
further studies into the mechanism of plasticity changes in PD and dystonia and 
importantly, highlight the therapeutic potential of TMS in both disorders 
 
7.1.1 Delineating the mechanism of increased cortical plasticity in PD 
 
Our data support the role of asymmetric hemispheric reorganisation in 
compensation for PD, however further studies should address the mechanism 
through which this might have been occurring. 
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1) Asymmetric functional cortical reorganisation in early PD may be a 
consequence of asymmetric BG output from the less and more affected sides. 
This issue could be addressed in longitudinal studies of clinically still unaffected 
individuals who are at a high risk of developing PD, such as carriers of PD 
genes that have  a high penetrance. In the potential study, changes in plasticity 
over time could be correlated with functional neuroimaging of the BG, such as 
FDG-PET and/or DAT-SCAN. 
 
2) An additional mechanism responsible for the asymmetry of LTP-like 
plasticity in early PD could be related to abnormal interhemispheric connectivity, 
consistent with the model of interhemispheric competition in the motor system. 
This model has been investigated in detail in stroke patients and implies that the 
affected hemisphere is disabled both by its own damage and by stronger 
inhibition from the unaffected hemisphere (Murase et al., 2004, Ward and 
Cohen, 2004). Extending the model of interhemispheric competition to cover our 
findings, reduced inhibition from the more to the less affected hemisphere could 
account for increased motor cortex plasticity in the less affected hemisphere. 
There is previous evidence for reduced transcallosal inhibition in PD, as 
demonstrated by shortening of the ipsilateral silent period (Priori et al., 1994) 
and reduced interhemispheric inhibition from the more to the less affected 
hemisphere in PD patients with mirror movements (Li et al., 2007, Spagnolo et 
al., 2013). However, no studies have so far investigated if interhemispheric 
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projections from M1 may affect LTP-like plasticity in the contralateral target 
hemisphere. 
 
3) A compensatory role of the cerebellum has been suggested in PD 
(Ballanger et al., 2008, Wu and Hallett, 2013). Recent work has shown that in 
healthy subjects, sensorimotor cortical plasticity as measured by the response 
to a facilitatory PAS protocol depends on the functional state of cerebellar 
output (Hamada et al., 2012b, Popa et al., 2013). If the response to PAS is 
modulated by inputs from the cerebellum, then an increase in cortical plasticity 
may be driven by potential compensatory influences from the cerebellum. This 
may be further investigated in early clinically asymmetric PD patients by 
studying how the response to PAS in each hemisphere changes after 
preconditioning the ipsilateral cerebellum with stimulatory and inhibitory TMS 
protocols. 
 
7.1.2 Therapeutic use of TMS in PD 
 
If increased sensorimotor cortical plasticity of the less affected hemisphere in 
early PD is an adaptive change that slows down progression of the motor signs, 
then further enhancing plasticity using non-invasive brain stimulation techniques 
may result in additional benefits for patients. This may be achieved by applying 
repeated sessions of stimulatory TMS protocols over the less affected side of 
early PD patients or even in the preclinical phase of disease. It would also be 
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interesting to investigate if the response to rTMS depends on the treatment 
status of the patients. In our study, we have not shown that early initiation of 
dopaminergic treatment affects the change in the PAS response that occurs 
with disease progression, however our sample was small and our study was not 
primarily designed to answer this question. 
 
7.1.3 Further defining the role of cortical plasticity in dystonias 
 
Previous work (Quartarone et al., 2003, Weise et al., 2006) and our study 
provide evidence that plasticity is abnormal in the primary dystonias, while we 
show that plasticity is normal in patients with secondary dystonia due to BG 
lesions, as it is in patients with psychogenic dystonia (Quartarone et al., 2009).  
This suggests that functional cortical involvement differs between various forms 
of dystonia. Further studies may address whether cortical plasticity and 
cerebellar function are involved in some other dystonias, such as drug-induced 
dystonias or Dopa-responsive dystonias. This could help to resolve the debate 
on whether there is a common pathophysiological model for all the dystonias or 
rather different forms of dystonia may have different faulty neuroanatomical 
networks. 
 
Furthermore, as all electrophysiological studies on primary dystonias have dealt 
with patients who have had at least several years history of dystonic symptoms, 
it is still not known if abnormal plasticity is present at the initial presentation of 
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the disease, as would be expected if enhanced plasticity is indeed 
pathophysiological trait that predisposes individuals to developing symptoms. 
Finally, we have shown that injection of BT injections temporarily reduces 
plasticity for a short period after the injections (Chapter 5), while it remains to be 
studied if chronic BT treatment affects plasticity in the long term. 
 
7.2 Methodological “lesson”: resolving controversies 
 
Increasing numbers of TMS studies in PD and dystonia have contributed to the 
progress in the electrophysiological characterization of BG diseases. 
Nevertheless, assometimes quite opposite findings have been recorded  in the 
same disease, confusion has occurred when interpreting the pathophysiological 
findings. For example, in PD, the response to PAS is typically reported as being 
reduced (Morgante et al., 2006, Ueki et al., 2006, Kawashima et al., 2013), but 
some studies have found the opposite, namely an increased response to PAS 
(Bagnato et al., 2006). Opposite findings exist also for iTBS induced cortical 
plasticity in PD (Suppa et al., 2011, Zamir et al., 2012). In dystonia, intracortical 
inhibition as measured by SICI or CSP has been reported as either reduced or 
normal (Hallett, 2011). These controversies can be explained by the details of 
the experimental protocols and also by the characteristics of the patients being 
studied. Although the average picture of electrophysiological characteristics in 
PD and dystonia (and other BG disease) may be best revealed by 
methodological studies on large-scale heterogeneous populations, we believe 
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that our four studies contribute to resolving some of the controversies, and have 
some important methodological implications: 
 
1) Our results show that the clinical asymmetry of PD is reflected in 
asymmetry of cortical TMS parameters. This fact might be one of the 
reasons for the conflicting findings in previous studies which did not take 
into account the side of symptom onset. The problem may be avoided if 
all the patients included in a study are tested on either more or the less 
affected side. 
 
2) By longitudinally studying the same PD patients, we have shown that 
electrophysiological abnormalities are not fixed, but rather change with 
disease progression. This implies that the disease duration can affect 
TMS measurements, thus contributing to the variability of results. It is 
therefore important that patients included in TMS studies have similar 
duration of parkinsonian symptoms. 
 
3) In dystonia patients, the response to an experimental plasticity protocol 
correlates positively with the time from previous BT injections. The 
implication is that in studies of dystonia, patients should all be treated 
with BT at the same time before commenicng the experiments. 
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4) Different forms of dystonia do not share the same pattern of 
electrophysiological abnormalities. We have shown differences between 
secondary and primary dystonia patients, and there is one study 
providing similar evidence for differences between genetic and non-
genetic causes of primary dystonias (Sadnicka et al., in preparation). 
Therefore, lumping patients with different types of dystonia together 
should better be avoided, as this may lead to heterogeneous results and 
add the confusion rather than increasing the knowledge of the 
pathophysiology of the dystonias. 
 
7.3. General limitations of the studies 
There are limitations associated with statistical analysis used, which I will avoid 
in my future studies. For example, the possibility of type I statistical error (“false 
positive”) may be minimized using Bonferonni corrections for multiple post-hoc 
comparisons and correlations. Type II statistical error (“false negative”) may be 
minimised if an optimum sample size is based on the power calculations for the 
expected responses from the previously published studies. I will also report the 
statistics and the p values of the non-significant results. Finally, I will express 
variability of the results not only in terms of measures of the central tendency 
(average values) +/- standard error of the mean, but also in terms of confidence 
intervals and effect size. This would allow not only more precise estimations of 
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how much the average values of the clinical and electrophysiological variables 
are likely to fluctuate but will also permit the results to be included in the future 
metanalysis studies. 
 7.4 Conclusions 
  
This work is focused on two intriguing movement disorders, PD and dystonia, in 
which functional reorganisation of the sensorimotor cortex seems to have an 
important pathophysiological role. Our approach was to study cortical plasticity 
and intracortical inhibition in these disorders, and in particular, the relation of 
these measures with other disease related factors, including duration of 
disease, etiology, and the impact of medical treatment.. 
 
We found that PD is initially characterised by an increase in sensorimotor 
plasticity, which probably reflects adaptive process that compensate for the 
presence of motor symptoms. However, with time plasticity decreases as this 
compensation is lost and the motor symptoms evolve further. Thus, a potential 
treatment approach to PD could be to intervene in a way that sustains or further 
increases sensorimotor cortical plasticity, aiming to slow down the progression 
of the motor signs. 
 
In dystonia, enhanced plasticity seems to represent a maladaptive trait of 
primary but not secondary forms of the disease. This may explain the well-
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known differences in their responses to treatments, as well as providing a 
rational basis for further therapeutic approaches. Non-invasive brain stimulation 
techniques that interfere with plasticity might be more appropriate in primary 
dystonias than in patients with secondary dystonias caused by structural brain 
lesions. 
 
In conclusion, brain plasticity should be understood as a process of constant 
adjustment to various situations, wheteher or not these are good or bad, short-
lived or enduring. As a consequence of this continuous process, manifestations 
of neurological disorders may not only depend on the impact of the disease 
pathology, but also on the brain’s potential to undergo plastic changes, adaptive 
or maladaptive. And even though we may be born with our brain having pre-
determined potential to undergo plastic changes, there may still be a prospect 
of interfering with plasticity for the good of a patient. With this in mind, the first 
step is to disentangle the functional significance of plasticity changes in 
neurological disorders, as this will eventually enable us to modify them in a 
desirable direction, inhibiting changes that lead to disease manifestation and 
enhancing those that help the patient.  
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